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 2. ABBREVIATIONS  
 
ABC  avidin-biotin-peroxidase complex 
ADAM  a disintegrin and a metalloproteinase 
ADAMTSs a disintegrin and metalloproteinase with thrombospondin motifs 
ARF   activation-resorption-formation  
ATPase   adenosine triphosphatase  
BCIP   5-bromo-4-chloro-3-indolylphosphate 
BMU   basic multicellular unit  
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FDA   United States Food and Drug Administration  
GM-CSF   granulocyte-macrophage colony-stimulating factor  
GMK   green monkey kidney (cell line)  
HSY   human salivary adenocarcinoma (cell line) 
IFN-γ   interferon-γ  
IL   interleukin 
ISH   In situ hybridizasion  
M-CSF   macrophage-colony stimulating factor  
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MMP  matrix metalloproteinase 
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PBMC   peripheral blood mononuclear cell  
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PCR   polymerase chain reaction  
PIV-2  Parainfluenza virus type 2 
PMMA   polymethylmethacrylate  
PGE   prostaglandin 
PTH   parathyroid hormone  
RANK   receptor activator of nuclear factor kappa B 
RANKL  receptor activator of nuclear factor kappa B ligand 
SDS   sodium dodecyl sulphate  
SEM   standard error of the mean  
SH3  Src homology 3  
SR   scavenger receptor 
TGF-α   transforming growth factor-α  
THR  total hip replacement 
TNF  tumor necrosis factor 
UHMWPE ultrahigh molecular weight polyethylene  
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 3. ABSTRACT 
 
Total hip replacement is the golden standard treatment for severe osteoarthritis refractory for 
conservative treatment. Aseptic loosening and osteolysis are the major long-term complications 
after total hip replacement. Foreign body giant cells and osteoclasts are locally formed around 
aseptically loosening implants from precursor cells by cell fusion. When the foreign body 
response is fully developed, it mediates inflammatory and destructive host responses, such as 
collagen degradation. In the present study, it was hypothesized that the wear debris and foreign 
body inflammation are the forces driving local osteoclast formation, peri-implant bone resorption 
and enhanced tissue remodeling. Therefore the object was to characterize the eventual expression 
and the role of fusion molecules, ADAMs (an abbreviation for A Disintegrin And 
Metalloproteinase, ADAM9 and ADAM12) in the fusion of progenitor cells into multinuclear 
giant cells. For generation of such cells, activated macrophages trying to respond to foreign debris 
play an important role. Matured osteoclasts together with activated macrophages mediate bone 
destruction by secreting protons and proteinases, including matrix metalloproteinases (MMPs) and 
cathepsin K. Thus this study also assessed collagen degradation and its relationship to some of the 
key collagenolytic proteinases in the aggressive synovial membrane-like interface tissue around 
aseptically loosened hip replacement implants. 
 
ADAMs were found in the interface tissues of revision total hip replacement patients. Increased 
expression of ADAMs at both transcriptional and translational levels was found in synovial 
membrane-like interface tissue of revision total hip replacement (THR) samples compared with 
that in primary THR samples. These studies also demonstrate that multinucleate cell formation 
from monocytes by stimulation with macrophage-colony stimiulating factor (M-CSF) and 
receptor activator of nuclear factor kappa B ligand (RANKL) is characterized by time dependent 
changes of the proportion of ADAMs positive cells. This was observed both in the interface 
membrane in patients and in two different in vitro models. In addition to an already established 
MCS-F and RANKL driven model, a new virally (parainfluenza 2) driven model (of human 
salivary adenocarcinoma (HSY) cells or green monkey kidney (GMK) cells) was developed to 
study various fusion molecules and their role in cell fusion in general. In interface membranes, 
collagen was highly degraded and collagen degradation significantly correlated with the number 
of local cells containing collagenolytic enzymes, particularly cathepsin K. 
 
As a conclusion, fusion molecules ADAM9 and ADAM12 seem to be dynamically involved in 
cell-cell fusion processes and multinucleate cell formation. The highly significant correlation 
between collagen degradation and collagenolytic enzymes, particularly cathepsin K, indicates that 
the local acidity of the interface membrane in the pathologic bone and soft tissue destruction. This 
study provides profound knowledge about cell fusion and mechanism responsible for aseptic 
loosening as well as increases knowledge helpful for prevention and treatment. 
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 4. INTRODUCTION 
 
In aseptic loosening, foreign body reaction is directed against microparticles that formed by 
corrosion and mircomovement between implant and bone. Peri-implant osteolysis develops as a 
consequence of an active biologic process involving the resorption of bone at the peri-implant 
sites and leads to loss of prosthetic fixation, dissection of the implant and extension of the 
effective joint space. The macrophages, foreign body giant cells, and osteoclasts that are present 
within the peri-implant tissues are derived from a common hematopoietic lineage, but their 
phenotypic genes, gene products and function are different to distinguish these cells from each 
other (Shen et al. 2006). Foreign body giant cells recognize, bind and phagocytose wear debris, 
while osteoclasts resorb mineralized bone matrix. Monocytes or macrophages are important 
precursory cells in the regulation of bone metabolism and destruction. 
Multinucleation is an essential step in the differentiation of osteoclasts and for osteolysis as 
mononucleated macrophages may not resorb bone efficiently. Polykaryon formation from 
mononuclear precursor is an important step in the osteoclast differentiation. Osteoclasts are the 
bone resorbing cells, which play an important role in the regulation of both healthy and diseased 
bone. As fusion molecules, ADAMs may be involved in cell-cell fusion processes and in myoblast 
fusion and possibly also in osteoclast fusion (Huovila et al. 1996, Galliano et al. 2000, Huppertz 
et al. 2006). Similar cell fusion is also essential for the formation of multinuclear foreign body 
giant cells typical for aseptic loosening. 
Bone is a dynamically remodeling tissue; the homeostasis is dependent on balanced bone 
resorption and formation. This soft tissue remodeling is adapted to structural and mechanical 
environment changes as a phenomenon of functional adaptation (Fung, 1990). Mature osteoclasts 
initiate the activation-resorption-formation (ARF) cycle and demineralization of bone and 
collagen degradation. Once activated, osteoclasts secrete protons and proteinases. Proteinases 
have been regarded as markers for inflammation and enhanced tissue remodelling. MMPs and 
cathepsin K are rate limiting and therefore, the most important proteinases in this process 
(Delaisse et al. 2000, Everts et al. 2006). The presence of various collagenases and cathepsin K in 
the synovial membrane-like interface membrane is necessary for collagen degradation. 
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 5. REVIEW OF THE LITERATURE 
 
5. 1 THR and aseptic loosening  
 
5.1.1 Total hip replacement 
 
Today nearly one million total hip replacements (THR) are carried out worldwide each year 
(Konttinen et al. 1997). Primary osteoarthritis and joint destruction caused by rheumatoid arthritis 
are the most frequent causes of hip pain and invalidity (Maynard et al. 1995). Severe primary or 
secondary osteoarthritis can be effectively treated using THR, which has considerably improved 
the quality of life of these patients (Laupacis et al. 1993). In the 1960s John Charnley developed 
the low-friction arthroplasty design consisting of a small-diameter metallic femoral head 
articulating with a polymeric acetabular cup (Charnley 1961). A small head was selected to 
minimize the area of the gliding surface and thus the formation of wear debris of the polymeric 
polyethylene cup. This concept was the most successful surgical procedure developed for 
replacing the hip joint (Lehtimäki et al. 1997, Heisel et al. 2004). The vast majority of total hip 
replacement prosthesis consists of femoral and acetabular components. Femoral stem is fixed to 
femoral medullary canal and is made titanium or chromiumcobolt. The stem is usually modular 
i.e. it consists of a separate head (ball). Acetabular cup is fixed to pelvis and is made of 
polyethylene or metal (Figure 1). The cup can be either monoblock or modular (Figure 1). 
Monoblock cups are made of metal. Modular cups contain metallic shell and liner. Liner (inner 
part) is made of polyethylene, metal (chromiumcobolt) or ceramic. Femoral heads are usually 
made of either metal or ceramic. Thus, typical bearing surfaces are metal/ceramic-on-
polyethylene, metal-on-metal and ceramic-on-ceramic. After surgery, fixation of uncemented 
components is based of friction. Later, bone ingrowns on implants rough surface. Cemented 
implants are fixed using ”bone cement” (polymethylmethacrylate) and achieve immidiatedy 
during surgery their maximal stability. In younger patients, survival rate of uncemented implants 
has been better when aseptic loosening has been end-point (Mäkelä et al. 2008a, Mäkelä et al. 
2008b). THR is a cost-effective artificial treatment with remarkable durability (Callaghan et al. 
004). 2 
 
Figure 1. Conventional uncemented total hip prosthesis with metal-on-polyethylene bearings 
 
5. 1. 2 Aseptic loosening 
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The most common long-term problem that restricts the patient’s daily activities after THR is pain 
associated with aseptic loosening and/or osteolysis. When a total hip prosthesis loses adequate 
fixation to bone it usually causes increasing pain and distinct changes develop into the 
radiographs. Extensive localized bone resorption resulting in loosening without infection was 
named aseptic loosening. Poor fixation leading to micromotion and the lack of initial stability and 
osseointegration of the implant are important factors of later symptomatic loosening (Munuera et 
al. 1992, Goodman et al. 1994). Mechanical cyclic loading, together with adverse host reaction to 
ultra-high molecular weight polyethylene wear debris and other foreign wear particles have been 
proposed as the main reasons for aseptic implant loosening. Implantation with the artificial joint 
leaves an open wound which is not replaced by scar tissue, because of the continuous movement 
of the prosthetic devices in the body (Konttinen et al. 1998). Wear debris produced from the THR 
cause a chronic inflammatory disorder, which can lead to peri-implant osteolysis. Aseptic 
loosening has been shown to be associated with this chronic foreign body type inflammation, 
which leads to activation of the local inflammatory cells, in particular those of the 
monocyte/macrophage lineage (Lassus et al. 1998, Shen et al. 2006). Synovial membrane-like 
interface tissue exists between the prosthesis/cement and host bone where inflammatory mediators 
are produced and contribute to periprosthetic osteolysis and implant loosening. It is evident that 
several inflammatory cells activated by foreign body reaction and their proinflammatory 
mediators like cytokines and degradative enzymes contribute to the pathogenesis of chronic 
aseptic inflammation and implant loosening. Macrophages and foreign body giant cells in the 
interface membrane surrounding loosened implants express cytokines associated with osteoclastic 
cells (Neale and Athanasou 1999). Some cytokines, e.g., interleukin (IL)-1, IL-6, and tumor 
necrosis factor (TNF)-α, have been detected in periprosthetic tissue in patients with loosening of 
the prosthesis (Konttinen et al. 1996, 1997). 
 
5. 1. 3 Synovial membrane-like interface tissue 
 
Synovial membrane-like interface tissue exists between the host bone and prosthesis. It is 
characterized by a cell-rich foreign body reaction although some areas are characterized by 
fibrosis containing mainly collagen fibers and elongated fibroblasts. Thus, there are two distinct 
morphologic areas a cell rich area containing macrophages and multinucleate giant cells, and 
fibrous area consisting of collagen fibres and elongated fibroblasts. A synovial lining-like 
structure is usually one to three cell layers thick and consists of fibroblast- and macrophage-like 
cells (Goldring et al. 1986, Jiranek et al. 1995, Goodman et al. 1998). 
 
Micromovement of the implants may lead to the formation of first fibrous implant capsule and 
later synovial memebrane-like interface tissue. Micromotion of the THR prosthesis might be due 
to necrosis produced in the superficial bone layer during implantation and cementing (Aspenberg 
et al. 1998), while implant components appear more stable in cementless prosthesis because of 
bone ingrowth (Little et al. 2006). Cyclic loading of a poorly fixed prosthesis may aggravate 
necrosis of peri-implant bone and prevent healing by bone fusion in cemented implants, whereas it 
can be healed in uncemented implants when motion stops. Early loading of prosthesis can also 
contribute to fibrous tissue ingrowth (Jasty et al. 1997). The pH in the interface tissue is low 
enough to lead to demineralization of peri-implant bone.
 
5. 2 Biomaterials and wear particles 
 
Hip joint is loaded during our daily activities. Because artificial hip contains bearing surfaces, 
motion leads to friction and formation of wear debris and foreign bodies (Konttinen et al. 2005). 
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 Such particles are particularly formed between the head and the cup, later is usually prepared of 
ultrahigh molecular weight polyethylene (UHMWPE) (Konttinen and Santavirta 2003). Foreign 
bodies are also formed elsewhere, e.g. between metal contact surfaces of stem vs. head, head vs. 
modular neck and polyethylene liner and acetabular shell. Debris, together with movement caused 
by loading, leads to irritation (Konttinen et al. 2005). Particles of prosthetic material stimulate 
host cells to release cytokines, which may cause chronic inflammation, bone loss and loosening of 
the prosthesis.
 
5. 2. 1 Biomaterials 
 
Currently metals, polymers and ceramics are used as biomaterials of the different components of 
hip replacement implants (Katti 2004). The standard for hip arthroplasty is to use 
polymethylmethacrylate (PMMA) fixed UHMWPE acetabular cup and a femoral stem made of 
metal (Bauer et al. 1999). However, use of uncemented implants is increasing rapidly. Stainless 
steel proved to be too corrosive and has relatively low fatigue strength and elasticity. Metals 
currently used for THR are able to carry sufficient load and resist bending and fatigue. For hip 
replacement, Co-based alloys and TiAl6V4 are commonly used. Cobalt-based materials are 
nonmagnetic and relatively corrosion resistant and wear resistant. The favourable biocompatibility 
and high corrosion resistance of titanium make it a good choice for femoral stems (Head et al. 
1995). However, titanium is not suitable for PMMA fixation due to its low resistance to abrasion, 
fretting and corrosion (Pohler 2000). 
 
Polymers are classified as biostable, bioabsorble and biodegradable polymers. Bone cement is 
polymerized methylmethacrylate, which is produced by mixing PMMA polymer powder and 
monomeric methylmethacrylate liquid in the presence of a catalyst. Under high tension or shear 
stress bone cement particles are formed. As a kind of conventional ceramics, alumina was 
approved as a material of ceramic-on-ceramic articulating hip for marketing by the United States 
Food and Drug Administration (FDA) in the United States in February of 2003, while ceramic-on-
ceramic implants have been used in Euorpe approximately 25 years. Hydroxyapatite 
(Ca10(PO4)6(OH)2) has good biocompatibility and forms a tight bond to periprosthetic bone, but 
has poor mechanical properties and brittleness restricts its applications (Bagambisa et al. 1993). 
 
The concept of biocompatibility refers to how harmonious is the implanted prosthesis in the body 
in host tissue and the capability to resist adverse tissue responses. The degree of biocompatibility 
of the implant material determines the type of tissue response. The less biocompatible the implant 
materials are, the more adverse host tissue responses they will produce. Using wear resistant and 
biocompatible materials is considered to increase longevity of the THR. The main direction of 
developing orthorpedic implants or materials is to pursue higher biocompatibility. For example, 
there is an attempt to increase biocompatibility using hard-on-hard bearing surfaces in order to 
decrease amount of wear (Santavirta 2003). 
 
5. 2. 2 Wear particles 
 
Prosthetic wear particles derived from implants are foreign body materials. The foreign body 
response seen in tissue samples is often initiated by foreign materials not easily removed or 
degraded. Therefore, wear particles are the main reasons for aseptic loosening and failure of THR 
impalnts. The host response to wear particles leads to osteolysis and the extent of osteolysis 
usually increases as the rate of wear increases (Dumbleton et al. 2002). Ultramicron size 
polyethylene particles are particularly likely to cause “particle disease”. Macrophage is the first 
cell type which responds to wear particles. The amount of polyethylene debris in a microscopic 
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 field was directly related to the number of macrophages that was visible by light microscopy 
(Schmalzried et al. 1992). When rubbing against metal femoral head, wear particles of UHMWPE 
are produced. The sizes of the UHMWPE particles isolated from tissues retrieved from failed total 
hip replacements has been in the range of 0.1–1000 μm diameter for patients, the maximum 
frequency distribution of the particles being in the range 0.1-0.5 μm, whereas analysis of the mass 
distribution revealed that the majority of the mass fell into size range >10 μm (Tipper et al. 2000, 
Howling et al. 2001). The mean size of the polyethylene particles was 0.5 μm, and of the metal 
particles 0.7 μm in metal-on-UHMWPE bearing suface. Wear particles from total hip prosthesis in 
the phagocytosable size range of 0.3–1.0 μm appear to be the most biologically active (Green et 
al. 1998, Ingham et al. 2005). Although larger fragments are relatively few, they contribute 
heavily to the total wear volume. A particle with size less than 7 µm in dimeter is engulfed, 
whereas those greater than 7 µm are generally assumed to be too large to be phagocytosed by 
macrophages and too large to contribute to the biological responses leading to osteolysis 
(Goodman et al. 1990). Particles of all biomaterials which are produced from bearing surface 
cause adverse biological reactions in periprosthetic tissues, which leads to the formation of 
osteolytic foreign body granulomas, inhibition of the bone formation and joint fluid production. 
 
The environments around the articulating surfaces and body interfaces may contribute to the 
generation of wear particles (Maloney et al. 1995). Tribology deals with friction, lubrication, and 
wear around the counterface. The wear by adhesion, abrasion, and corrosion between the primary 
bearing surfaces is considered the most important source of wear particles (Schmalzried and 
Callaghan 1999). Cyclic loading and micromotion between interfaces are considerable factors 
contributing to wear (Aspenberg and Herbertsson 1996, Konttinen et al. 2005). More than three 
million steps per year potentially generate hundreds of billions of polyethylene and metal 
particles. Abrasive wear occurs when surfaces of different hardnesses move against each other, 
for example, the harder metal surface scratches the surface of the softer UHMWPE material. In 
total hip prostheses polyethylene wear is an important source of abrasive wear as the metallic 
femoral head is so much harder than the polyethylene. Polyethylene particles are transported by 
pseudosynovial fluid to the synovial membrane-like interface membrane where they are 
phagocytosed by macrophages. The macrophages then release chemokines, inflamamatory 
cytokines and other mediators that stimulate the development of an inflamed granulomatous tissue 
adjacent to the bone. Eventually, osteoclasts are formed and/or activated to resorb bone leading to 
peri-implant osteolysis and loosening of the prosthesis (Shen et al. 2006). Many cytokines are 
present in the interface tissue around loosening implants and different types of prosthetic particles 
may induce different patterns of cytokines. Chemical composition of wear particles modulates the 
biological response, for example, wear particles of titanium alloys (TiAlV or TiAlNb) containing 
different concentrations of vanadium or niobium induced the expression of different osteolytic 
factors (Rogers et al. 1997). Particle surface chemistry also affects the activation of macrophages 
cytokine and enzyme production (Xing et al. 2002). Understanding the mechanism and effects of 
different biomaterials regulating osteoclast formation and activity may provide a way of selecting 
suitable biomaterials that should prolong the life time of implants. 
 
5. 3 Osteoclastogenesis 
 
Osteoclasts are bone resorbing cells, which play an important role in the regulation of both 
healthy and diseased bone. They are derived from haematopoietic cells of the mononuclear 
phagocyte progenitor (Burger et al. 1982). It has been earlier described that both macrophage-
colony stimulating factor (M-CSF) (Xu et al. 1997) and receptor activator of nuclear factor kappa 
B ligand (RANKL) (Mandelin et al. 2003) found in the interface tissue are necessary to stimulate 
osteoclastogenesis (Fuller et al. 1998, Haynes et al. 2001). Tissue destructive factors such as 
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 hydrochloric acid and proteinases (e.g. cathepsin K) lead to the dissolution of bone mineral 
(hydroxyapatite) and bone tissue. 
 
5. 3. 1 Macrophage activation in aseptic loosening 
 
Wear particle and cyclic load may together contribute to the activation of macrophages and an 
enhanced production of a set of cytokines, such as IL-1, IL-6, TNF-α, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), prostaglandin E2 (PGE2), M-CSF and transforming growth 
factor-α (TGF-α) (Ferrier et al. 2000, Green et al. 1998, Matthews et al. 2001). Use of hip 
implants always lead to the production of implant-derived particles, of which 
polymethylmethacrylate (PMMA) particles and the “cement disease” first draw attention and lead 
to the development of uncemented hip implants to avoid this complication. Later, when also other 
particles were found to be able to induce such reactions, the name of the condition was changed to 
“particle disease”. Thus, metal and especially ultra-high molecular weight polyethylene wear 
debris were also shown to be able to induce this host response. Wear debris leads to host reaction, 
to produce multinuclear giant cells from activated macrophage precursors as part of a foreign 
body reaction. Here the noxious stimulus, however, is of inorganic nature and can not be 
eliminated by the phagocytosing cells. Therefore, the response produced is chronic to its nature. 
Metallic implants are always surrounded by implant capsule, which in loosening develops into a 
synovial membrane-like interface membrane. It contains three principal cell types, macrophages, 
giant cells and fibroblasts, but naturally also blood and probably lymphatic vessels as well. Large 
amounts of wear debris are always detected extra- and/or intracellularly in interface tissue. 
Adverse responses of tissue to wear debris, fluid pressure waves caused by micromotion, 
proteinases, effective joint space and mechanical failure lead to the formation of synovial 
membrane-like interface tissue characterized by a foreign body reaction (Santavirta et al. 1991). 
Giant cells originate from the fusion of mononucleated precursors that belong to the mononuclear 
phagocyte lineage (Vignery 2000). As part of the host response, circulating monocytes make an 
initial tethering contact to activated endothelial cells and finally transmigrate to tissue in great 
numbers to form macrophages in order to get rid of particles. Macrophages activated by particles 
can secrete chemotactic cytokines so that they may play a role in induction of endothelial cell 
adhesion or the recruitment of osteoclast precursors from the vasculature by cytokine signaling 
(Frokjaer et al. 1995). The macrophage activation is influenced by particle chracteristics, like their 
size, shape, rigidity, charge and chemical structure. Activated macrophages participate in the 
formation of osteoclasts. Soluble stimuli, like M-CSF and RANKL or pseudosynovial peri-
implant fluid, can also induce macrophages to form osteoclasts (Mandelin et al. 2005). 
 
5. 3. 2 Fusion of osteoclast progenitors 
 
Particles, together with cyclic loading and implant-host interface micromovement are associated 
with macrophage accumulation and activation. Cytokines released by activated macrophages in 
turn stimulate monocyte recruitment and osteoclast precursor (monocyte/macrophage) 
proliferation and their differentiation in the interface tissue. The large numbers of macrophages 
present in the interface tissues have a potential capacity to form osteoclasts (Sabokbar et al. 1997). 
A key step in the giant cell formation is the fusion of mononuclear precursor cells together. Cell 
fusion need some preceeding preparatory steps, including cell accumulation, cell adhesion and 
membrane fusion. Monocyte trafficking and cellular movement regulated by chemokines and 
cytokines are essential for cell accumulation (Mackay et al. 2001, Muller et al. 2001). Both the ß1 
and ß2 integrins play important role in monocyte/macrophage adhesion (McNally et al. 2002). Till 
now, membrane fusion is not well understood at the molecular level. The study of fusion proteins 
derives from studies of the viral fusion proteins, found in the membranes of enveloped viruses 
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 (Hernandez et al. 1996). Fusion molecules mediate membrane fusion in part through overcoming 
the repulsive forces of lipid bilayers. Macrophages are activated during multinuclear cell fusion 
and fusion-specific molecules may be induced in polykaryon-directed macrophage activation 
(Vignery et al. 2000, Ma et al. 2003). 
 
5. 3. 3 Molecules involved in osteoclast formation 
 
Activated macrophages produce high level of M-CSF which is improtant for osteoclast formation 
and peri-implant bone resorption. M-CSF is also essential for the monocyte–macrophage lineage 
cells proliferation, differentiation and survival (Flanagan et al. 1998). M-CSF was found in 
synovial-like membrane interface tissue and in the synovial fluid obtained from patients with 
aseptic loosening (Xu et al. 1997). It is important to note that M-CSF receptor is also present on 
the surface of macrophages and foreign body giant cells in the peri-implant tissues so the locally 
produced M-CSF can act in an auto- or paracrine fashion (Neale et al. 1998). 
 
In osteobiology RANKL is an essential cytokine, which belongs to TNF superfamily. Haynes and 
coworkers demonstrated for the first time that arthroplasty-derived adherent cells from revision 
tissue samples including macrophages and fibroblasts expressed RANK (receptor activator of 
nuclear factor kappa B) and RANKL (Haynes et al. 2001). RANKL together with M-CSF induce 
human osteoclast formation in vitro, but it may be that osteoclasts are formed in a RANKL 
independent way supported by interleukin-6 and interleukin-11(Kudo et al. 2003). Particle-related 
inflammatory response in the periprosthetic tissues after total hip arthroplasty is associated with 
up-regulation of the RANKL/RANK/OPG (osteoprotegerin) system (Mandelin et al. 2003). 
 
RANK belongs to the TNF receptor family and is RANKL receptor on osteoclast precursors 
(Anderson et al. 1997). RANK mRNA is present on osteoclasts and/or foreign body giant cells in 
interface tissues (Crotti et al. 2004). RANK is capable of initiating osteoclastogenic signal 
transduction after ligation with RANKL expressed by osteoblasts, fibroblasts, and bone marrow 
stromal cells or found in soluble form in the interstial fluid. TNF-α via its type 1 receptor 
stimulates RANKL induced osteoclastogenesis by coupling of RANK and signal transduction 
(Zhang et al. 2001). Binding of RANKL to RANK activates several distinct cytoplasmic 
signalling pathways that lead to monocyte fusion and further activation. OPG, osteoclastogenesis 
inhibitory factor, is a secreted member of the TNF receptor family that lacks a transmembrane 
domain. OPG is expressed in human osteoblasts and stromal cells and it inhibits RANKL-related 
osteoclastogenesis (Simonet et al. 1997). OPG also inhibits osteoclast formation induced by joint 
fluid from patients with failed total hip arthroplasty (Itonaga et al. 2000). The balance of RANKL 
and OPG in peri-implant tissue may correlate with biocompitibility of implant and interface tissue 
(Mandelin et al. 2003). 
 
Table 1. Cytokines and growth factors that influence osteoclast differentiation and activity 
 
Factors Effects References 
Receptor activator of 
nuclear factor kappa B 
ligand 
induces osteoclast formation, 
differentiation and activation 
Lacey et al. 1998
Haynes et al. 2001 
Macrophage-colony 
stimulating factor 
stimulates osteoclast differentiation, 
migrate to resorptive sites, maintain 
osteoclast survival  
Neale et al. 2002
Sundquist et al. 1995
Fuller et al. 1993
 
 
 
 
 
 
 
 
Tumor necrosis factor-α 
and -β 
stimulates the formation of 
osteoclast, bone resorption 
Pfeilschifter et al. 1989
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 Interleukin-1  induces bone resorption and 
osteoclast-like cell formation 
Pfeilschifter et al. 1989
 
Interleukin-6 induces osteoclast formation 
 
Kurihara et al. 1990 
Roodman et al. 1992
Interleukin-7 increases osteoclast formation, 
induces bone loss 
Ross 2003 
Toraldo et al. 2003 
Interleukin-11 induces osteoclast formation Girasole et al. 1994
Interleukin-17 stimulates osteoclast formation, 
increased bone resorption 
Van bezooijen et al. 1999
Transforming growth 
factor-α  
increases bone resorption Yates, et al. 1992 
 
Epidermal growth factor 
 
stimulates bone resorption, 
enhances osteoclast recruitment 
Saddi et al. 2008
Vascular endothelial 
growth factor 
activates osteoclast migration, 
stimulate bone resorption 
Henriksen et al. 2003 
Zhang et al. 2008
Insulin-like growth factor-
I 
stimulates osteoclast differentiation Wang et al. 2007
Platelet-derived growth 
factor 
stimulates bone resorption Zhang et al. 1998
Bone morphogenetic 
protein-2 
induces osteoclast differentiation 
and survival
Itoh et al. 2001
Bone morphogenetic 
protein-7 
induces osteoclastogenesis and 
recruitment of osteoclast 
Hentunen et al. 1995
Leukaemia inhibitory 
factor 
stimulates osteoclast differentiation Heymann et al. 1997 
Richards et al. 2000
Fibroblast growth factor-2 
 
promotes osteoclast recruitment, 
formation, differentiation 
Collin-Osdoby et al. 2002
Fibroblast growth factor-
18 
induces osteoclast formation, 
stimulate bone resorption 
Shimoaka et al. 2002
Prostaglandin E2  increase osteoclast acidity, induce 
osteoclast differentiation
Anderson et al. 1986 
Liu et al. 2006
Monocyte chemotactic 
protein-1 
induces osteoclast differentiation,  
chemotactic recruitment 
Kim et al. 2006 
Capellen et al. 2002 
Li et al. 2007
Macrophage inflammatory 
protein-1 
induces osteoclast differentiation, 
survival, activation 
Oba et al. 2005 
Okamatsu et al. 2004
 
 
 
 
 
 
 
 
Enhancers 
Stromal derived factor-1 Promotes chemotactic recruitment, 
stimulates cell fusion  
Liao et al. 2005 
Wright et al. 2005 
Yu et al. 2003
Osteoprotegerin inhibits osteoclastogenesis 
inhibits osteoclastic bone resorption 
Theoleyre et al. 2003
Hamdy et al. 2005
Interferon γ suppresses the formation and 
maturation of osteoclasts 
Fox et al. 2000
Takahashi et al. 1986
Interferon β inhibits osteoclast differentiation Alliston et al. 2002
Interleukin-4 inhibits osteoclasts formation 
inhibits bone resorption 
Shioi et al. 1991 
Riancho et al. 1993
 
 
 
 
 
 
 
 
Inhibitors 
Interleukin-10 inhibits osteoclastogenesis Evans and Fox, et al. 
2007
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 Interleukin-13 inhibits osteoclast differentiation 
and bone resorption 
Palmqvist et al. 2006
Interleukin-18 Inhibits osteoclast formation Horwood et al. 1998
Nitric oxide inhibits bone resorption Brandi et al. 1995
Endothelin inhibits bone resorption  Alam et al. 1992
Granulocyte–macrophage 
colony-stimulating factor  
short term for stimulating osteoclast 
differentiation, long term for 
inhibiting osteoclasts formation 
Horwood et al. 1998  
Hodge et al. 2004 
Park et al. 2007
 
 
Dual 
factors Transforming growth 
factor β 
Low concentrations stimulates 
osteoclast formation, high 
concentrations inhibitory 
Shinar et al. 1990 
Hattersley et al. 1991 
Janssens et al. 2005
 
 
Table 2. Hormones (systemic factors) that influence osteoclast differentiation and activity 
 
Factors Effects References 
1,25-
dihydroxyvitamin D3
induces osteoclast formation Thavarajah et al. 1991
Parathyroid hormone  
and related peptide 
osteoclast activation 
stimulatory effects 
Blair et al. 2004 
Chiusaroli et al. 2003
 
 
 
 
Enhancers 
Glucocorticoids stimulate osteoclast generation 
increase bone resorption 
Sivagurunathan et al. 
2005, Yao et al. 2008
Testosterone inhibits osteoclast formation and 
bone resorption 
Michael et al. 2005
Estrogen inhibits osteoclast formation Oursler et al. 1994
 
 
Inhibitors 
Calcitonin inhibits osteoclast development 
and bone resorption 
Ikegame et al. 1996
Cornish et al. 2001
 
Prostaglandin E2 (PGE2) affects both osteoblastic cells and cells of the mononuclear phagocyte 
lineage. The influence of PGE2 on osteoclast formation and osteoclastic bone resorption may be 
dependent on the dose administered and stages of osteoclast differentiation (Quinn et al. 1994). 
Furthermore, PGE2 increases acid secretion of osteoclasts (Anderson et al. 1986). Interleukin 11 
and 1, 25-dihydroxyvitamin D3 also modulate osteoclast formation (Girasole et al. 1994). 
Interleukin 11 is an important component of cytokine network mediating osteoblast-osteoclast 
communication in periprosthetic osteolysis and in the loosening of THR implants (Xu et al. 
1998). In the presence of interleukin 11 osteoclasts showed a high degree of resorption (Girasole 
et al. 1994) (Table 1, 2, Figure 2). 
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Figure 2. Molecular pathway of osteoclast (OCL) formation. ADAMs as fusion molecules might 
involve in osteoclast progenitor cells fusion to form osteoclasts. Osteotropic enhancers induce 
upregulation of RANKL on stromal cells and osteoblasts. RANKL then binds the RANK receptor 
on osteoclast precursors and induces osteoclast formation. 1, 25 (OH)2D3, 1,25-dihydroxyvitamin 
D3; PGE2, Prostaglandin E2; PTH/PTHrP, Parathyroid hormone/related peptide; IL-1 Interleukin-
1; IL-6 Interleukin-6; IL-11, Interleukin-11. 
 
5. 4 ADAMs and cell fusion 
 
5. 4. 1 ADAMs 
 
The ADAMs (an abbreviation for A Disintegrin And Metalloproteinase) are a family of 
multidomain transmembrane glycoproteins which always have a disintegrin and a metalloprotease 
domain. At present, more than 30 members of ADAM family (Table 2) and 19 different 
ADAMTSs (a disintegrin and metalloproteinase with thrombospondin motifs) have been found 
(Blobel et al. 2005, Jones et al. 2005). ADAMTS also have a thrombospondin TS domain. Based 
on studies it is clear that ADAMs mRNAs are present in a wide range of mammalian tissues. The 
extracellular structure of ADAMs shares a high sequence homology and domain organization with 
snake venom metalloprotease (Schlondorff et al. 1999). The term disintegrin was first used to 
describe viper venom protein which binds tightly to the platelet integrin receptor and blocks the 
interaction of integrin with its ligand to inhibit platelet aggregation (Gould et al. 1990, McLane et 
al. 1998). They also seem to be involved in some diseases such as inflammation and cancer. 
ADAMs belong to the zinc protease superfamily. Their metalloprotease domains are 
proteolitically active and can degrade extracellular matrix components and can shed other 
proteinases, adhesion molecules, cytokines and their receptors (Black et al. 1998). The disintegrin 
domain of ADAMs is a ligand for integrins. Some ADAMs contain a putative fusion peptide in 
the cysteine-rich domain that is involved in both membrane fusion and osteoclast formation 
(Figure 3) (Abe et al. 1999, Seals et al. 2003). Viral fusion peptides are short segments of mostly 
hydrophobic amino acids found in a transmembrane subunit of viral fusion proteins which are 
primarily involved in virus-host target cell fusion. A fusion peptide penetrates host cells like a 
sword, penetrating the lipid bilayer of the host cell. Thus, the anchoring fusion peptide propels the 
virion close enough to the host target cell membrane to be able to trigger virus-host cell fusion. 
 18
 (White, 1992, 1995, White et al., 1996). ADAM1, 5, 8, 9, 11, 12, 14 and 20 have been reported to 
have this hydrophobic homologous sequence (Huovila et al. 1996, Duffy et al. 2003). 
 
 
 
 
 
Figure 3. Domain structure of ADAMs (Modified from Seals et al. 2003). 
 
 
 
 
Table 3. Human ADAMs 
 
ADAM Common name(s) Potential functions Expression 
MP active Integrin binding
 2 fertilin-β, PH-30 β sperm/egg 
binding/fusion 
testis1   √ 
 7 epididymal apical protein I   epididymis2   
 8 murine cell-surface antigen 2, CD156  granulocytes/ monocytes3  √ (d)  
 9 meltrin-γ, 
metalloprotease/disintegrin/cysteine-rich 
protein 9 
sheddase, cell 
migration/fusi-on 
widely expressed4,5 √ (d)  √ 
10 kuzbanian, mammalian disintegrin-
metalloprotease, SUP-17 
sheddase; cell fate 
determination 
widely expressed 6  √ (d)  
11 metalloprotease/disintegrin/cysteine-rich 
protein  
putative tumor 
repressor 
brain7   
12 meltrin-α sheddase, myoblast 
fusion 
widely expressed 8-10  √ (d)  √  
15 metargidin, 
metalloprotease/disintegrin/cysteine-rich 
protein 15 
cell/cell binding widely expressed 11  √ (p)  √ 
17 Tumour necrosis factor-α convertase sheddase widely expressed 12  √ (d)  
18 testis metalloprotease/disintegrin/cysteine-
rich protein III 
 testis13   
19 meltrin-β, metalloprotease and disintegrin 
dendritic antigen marker 
sheddase, dendritic 
cell development 
widely expressed 8,14  √ (d)  
20   testis15  √ (p)  
21   testis15  √ (p)  
22 metalloprotease/disintegrin/cysteine-rich 
protein 2 
 brain7,16   
23 metalloprotease/disintegrin/cysteine-rich 
protein 3 
cell adhesion/ neural 
development 
brain7,17   √ 
28 metalloprotease/disintegrin/cysteine-rich 
protein-L 
immune surveillance epididymis, lung, 
lymphocytes18-20
 √ (d)  √ 
29   testis21,22   
30   testis21  √ (p)  
33  genetically linked to 
asthma 
widely expressed 23  √ (p)  
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1 Gupta et al. 1996; 2Lin et al. 2001; 3Yoshiyama et al. 1997; 4Weskamp et al. 1996; 5Hotoda et 
al. 2002; 6Chantry and Glynn 1990; 7Sagane et al. 1998; 8Yagami-Hiromasa et al. 1995; 9Harris 
et al. 1997; 10Gilpin et al. 1998; 11Kratzschmar et al. 1996; 12Patel et al. 1998; 13Frayne et al.
2002; 14Kurisaki et al. 1998; 15Poindexter et al. 1999; 16Harada et al. 2000; 17Cal et al. 2000; 
18Roberts et al. 1999; 19Howard et al. 2000; 20Howard et al. 2001; 21Cerretti et al. 1999; 22Xu et 
al. 1999; 23Yoshinaka et al. 2002  
MP active refers to either predicted (p) or already demonstrated (d) activity based on the amino 
acid sequence of the catalytic active site in metalloprotease domain 
 
ADAM12 is a member of ADAMs family, which has been implicated in cell adhesion, cell fusion 
and fusion signalling (Wolfsberg et al. 1995). ADAM12 comprises a pro-domain, a 
metalloprotease domain, a disintegrin domain, a cystein-rich domain, an epidermal growth factor 
(EGF)-like domain, and a transmembrane domain with an attached cytoplasmic tail. The 
disintegrin domain contains a non-RGD (arginine-glycine-aspartic acid) group, which has been 
shown to support cell adhesion mediated through integrin receptors (Zolkiewska et al. 1995). 
Cysteine-rich domain can act as a ligand for cell-adhesion molecules which can promote the 
fusion protein activity of this domain (Schlondorff et al. 1999). The cytoplasmic domain contains 
several motifs potentially involved in fusion associated signal transduction (Huovila et al. 1996). 
Furthermore the cytoplasmic tail interacts with the actin cytoskeleton by directly binding to α-
actinin-1 and -2 (Galliano et al. 2000). α-actinins form direct links between the cellular actin 
cytoskeleton and cytoplasmic tail of ADAM12. This may explain some of the gross changes in 
cell morphology that occur during the cell fusion. Thus, the disintegrin, cysteine-rich and/or EGF 
repeat regions and the cytoplasmic tail of ADAM12 seem to promote cell fusion. It was reported 
that myotube fusion requires fusion molecule ADAM12 (meltrin-α, Yagami-Hiromasa et al. 
1998), while macrophage-derived giant cells and osteoclasts is the result of cell-cell fusion of 
mononuclear precursors via ADAM8 (Choi et al.2001). 
 
Another ADAM, ADAM9 has been found to be involved with proteolysis, cell adhesion and cell 
fusion. The metalloprotease domain of ADAM9 contains structures necessary for metalloprotease 
activity. Cysteine-rich domain can be involved in macrophage membrane fusion (Puissegur et al. 
2007). All the cysteine residues in the disintegrin and cysteine-rich domains are engaged in 
disulfide bonds and the overall disulfide bond configuration was found to be essential for the cell 
adhesive potential of the cell (White et al. 2003). It was shown that expression of ADAM9 mRNA 
enhanced by either RANKL+M-CSF or anti-CD98 antibody stimulation was associated with an 
accelerated monocytes fusion process (Namba et al. 2001). ADAM9, known as meltrin-γ, has a 
complex and multifunctional domain structure, may play multiple roles during the cell fusion 
procedure. Like ADAM1 (fertilin-α), it contains a fusogenic peptide in its cysteine-rich domain. 
Synthetic peptides corresponding to this fusion peptide, when reconstituted into liposome or 
incorporated in lipid bilayers, supported the proposed function in membrane fusion (Martin et al. 
1998). The MMPs could be transported by cyclic loading and pseudosynovial fluid to the interface 
membrane from the site produced. There they can participate in the degradation of the 
extracellular matrix (ECM) and expansion of the effective joint space as an essential part of the 
aseptic loosening. ADAM9 has metalloproteinase domain with somewhat similar proteolytic 
functions as MMPs. The metalloprotease domain of ADAM9 contains cysteine switch, furin 
cleavage, catalytic and Met-turn sites (Birkedal-Hansen et al. 1995, Pei et al. 1995, Mohan et al. 
2002). The catalytic site of metalloproteinases contains a zinc binding consensus sequence 
HEXXH (Wolfsberg et al. 1993). It may cleave basement membrane components and degrade 
extracellular matrix in loosening hip implants. Cytokines and their receptors play important roles 
in aseptic loosening (Konttinen et al. 1997). ADAM9 may mediate shedding of both cytokines 
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 and their receptors and thus regulate their activity (Amour et al. 2002). Adhesive ECM molecules 
may bind to the surface of the implant and thus facilitate binding of the host cells to the surface of 
the implant. This may help binding of bone cells to the surface of the implant, which may 
facilitate osseointegration of the prosthesis. Degradation of ECM may impair this fixation to bone, 
extend the joint space and loosen the implant. The disintegrin domain of ADAM9 has been shown 
to interact with the αvß5 integrin receptor (Zhou et al. 2001). Integrins regulate many cellular 
events, including adhesion and migration. The interaction between ADAM9 and αvß5 has been 
shown to regulate of IL-6 production (Karadag et al. 2006), while IL-6 produced in periprosthetic 
interface tissue may contribute to osteolysis of the nearby bone (Konttinen et al. 2002). The 
cytoplasmic tail of ADAM9 contains Src homology 3 (SH3) binding motifs (Weskamp et al. 
1996) and may interact with actin cytoskeleton and participate cell signalling because SH3 
associating with the actin cytoskeleton indicates that this domain might serve to bring together 
signal transduction proteins and their targets or regulators to the membrane cytoskeleton 
(Musacchio et al. 1992). 
 
5. 4. 2 Cell fusion 
 
Membrane fusion belongs to the most fundamental processes in living organism. Membrane 
fusion events are generally classified in three types: intracellular fusion, virus–cell fusion and 
cell–cell fusion. Cell–cell fusion is required for processes as diverse as fertilization, the formation 
of bone and placenta, and myogenesis (Jahn et al. 2003). Formation of multinucleated cells has 
two main effects on macrophages: it increases the size of the cells and enhancing the number of 
nuclei. Multinucleation of macrophages accompanied with functional phenotype changes is an 
essential step in osteoclast formation because mononucleated macrophages do not resorb bone 
efficiently. From an energetic point of view, the advantage of multiple nuclei is that to transport 
proteins and/or RNA from the nucleus to where they are needed in the cell could save more 
energy by having more nuclei spread around the cell. This might be particular useful for foreign 
body giant cells in interface tissue to destroy wear particles or for osteoclasts to resorb bone. The 
higher number of nuclei the multinucleated giant cells have, the bigger is the size of the targeted 
particles or bone surface area, which can be phagocytozed and eventually destroyed (Vignery et 
al. 2005). 
 
In paramyxovirus-to-host cell fusion the fusing virion membrane and host cell membrane are first 
brought into close contact and docked to each other. This occurs with the help of the 
hemagglutinin-neuraminidase on the surface of the virus, which binds to its sialic acid-containing 
receptor on the surface of the host cell. This interaction triggers the close-by latent fusion protein 
(F protein) trimers to undergo conformational changes so that they expose their second hidden 
hydrophobic fusion peptide domain. These now exposed hydrophobic viral fusion peptides insert 
into the host (target) cell membrane. Two of the anchoring fusion proteins then again fold, now so 
that their two trimeric hydrophobic domains (the transmembrane domain in the virion membrane 
and the fusion peptide domain in the host cell membrane) aline in an anti-parallel fashion in a 
structurally strong 6-helix bundle. This power stroke brings the virion membrane and host cell 
membrane together leading first to exoplasmic virus-host cell fusion and formation and expansion 
of the initial pore between the virus and host cell (Lamb et al. 2006). Thus, the viral fusion protein 
helps the viral envelope to fuse directly with the plasma membrane of its host target cell 
(Moscona 2005). 
 
There are plenty of studies about virus–cell fusion. However, the number of studies of virally 
induced host cell fusion and syncytium formation between infected and non-infected cells are 
sparse. Fusion of virally infected cells with adjacent uninfected cells forms large multi-nucleated 
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 cells called syncytia. The fused mass of the cells is called "syncytium". This virus induced host 
cell fusion is much more complex than virus–cell fusion, because there are many more receptors 
and glycoproteins on the cell surface than there are on the surface of an enveloped virus. Signal 
transduction and subsequent cell activation is an intricate multi-step mechanism mediating 
membrane fusion in which membrane lipids (phospholipids and cholesterol) are tightly involved. 
Interaction of host cells with neighboring cells bearing surface fusion molecules is required for 
syncytium formation. Syncytium formation and generalized cell fusion are potentially important 
mechanisms mediating virally induced cytotoxic effects because the giant cells die soon after they 
are formed (Lifson et al. 1986 a, b). Therefore, cell fusion of virally infected cells with 
neighboring cells to form multinucleated syncytia contributes to the pathogenic effects of virus. 
Multinucleated giant cells originating from monocyte-macrophages are associated with 
granulomatous lesions formed in response to viruses, bacteria or foreign bodies. We hypothesized, 
that such molecules of mammalian origin could contribute to virally induced host cell-host cell 
fusion and would also otherwise have already been recognized for their role in other, non-virally 
induced mammalian cell-cell fusion events. 
 
Myoblast fusion is a prerequisite for skeletal muscle differentiation, characterized by 
mononucleated myoblasts fusing to multinucleated muscle fibers (Wakelam et al. 1985). Proteins 
involved in myoblast fusion include cell-adhesion molecules, metalloproteinases, calmodulin, 
protein kinases and phospholipases (Horsley et al. 2004). Meltrin-α (ADAM12) was cloned from 
a myoblast source. It showed a restricted expression pattern that correlated well with early skeletal 
muscle development and muscle regeneration (Borneman et al. 2000). Another important step of 
myoblast fusion is that the fusion competent cells rearrange their actin cytoskeleton. 
 
In the process of macrophage fusion to osteoclast, RANKL instructs macrophage precursors to 
fuse. Other molecules identified as critical for the fusion include macrophage fusion receptor and 
its ligand CD47. They contribute to polykaryon formation as adhesion factors (Han et al. 2000, 
Helming and Gordon 2007). Dendritic cell specific transmembrane protein is also essential for 
multinucleation, but it need to trigger some membrane bound fusion molecules to initiate fusion 
(Yang et al. 2008, Vignery 2005). ADAMs might be just such kind of molecules which contain 
putative fusion peptide to start the fusion process. 
 
5. 4. 3 Role of ADAMs in cell fusion 
 
Cell–cell fusion reactions are critical in some developmental processes. Some ADAMs are 
expressed and participate in several cell fusion events, such as fusions of sperm–egg to form the 
zygote requiring ADAM1 and ADAM2 (Blobel et al. 1992, Cho et al. 1998), myoblasts to form 
myotubes regulating by ADAM12 (Galliano et al. 2000) and monocytes to form osteoclasts 
associating with ADAM8 (Mandelin et al. 2000), ADAM9 and ADAM12 (Verrier et al. 2004). In 
certain specialized tissues, such as placenta, fusion of cytotrophoblasts generates a protective and 
nutritive layer for the developing embryo (Huppertz et al. 2006). Proteins involved in sperm-egg 
fusion that may be considered as the most important cell fusion of life are ADAM1 and 2 (Waters 
et al. 1997). ADAM8 increases osteoclast formation when present in the fusion stage and it plays 
a role in the later stages of osteoclast differentiation (Choi et al. 2001). Meltrin-α (ADAM12) not 
only participates and regulates myoblast fusion but also osteoclast differentiation (Abe et al. 
1999). Among all these ADAMs 8, 9, 10, 12, 15, 17, and 28, which are expressed in osteoclast 
precursors and in mature osteoclasts, ADAM8 and ADAM12 may play an important role in the 
early stages of osteoclast formation (Verrier et al. 2004). 
 
Due to their role in other cell-cell fusion events, ADAMs form also good candidate molecules 
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 which might paticipate in virus induced cell-cell fusion. Fusion competent viruses might overtake 
host cell fusion system temporarily to their own use by overexpressing host’s own fusion peptides 
to promote cell-cell fusion and spreading of virus by just infected one cell. Using this kind Trojan 
horse strategy virus can spread efficiently and safely. 
 
5. 5 Bone destruction 
 
Aseptic loosened implants are always surrounded by a synovial membrane-like interface 
membrane, which is characterized by chronic inflammation (Atkins et al. 1997). Synovial-like 
lining and the potential space, an extension of the joint space, is the factual sign of loosening. It 
was first demonstrated by Harris and coworkers who performed arthrographies of totally replaced 
hip joints just prior to revision operation. It was possible to trace spreading of the intra-articularly 
injected contrast medium to this extended joint space which in some cases seemed to surround the 
whole implant. This interface is rich in tissue destructive collagenolytic enzymes which play 
importnant role in peri-implant bone destruction. Localized bone loss and local bone erosions are 
mainly produced by osteoclasts (Gravallese et al. 1998). Increased osteoclastic bone resorption 
plays an important pathogenic role in aseptic loosening. 
 
 
5. 5. 1 Osteoclast function 
 
Bone is a dynamically remodeling tissue, whose homeostasis balanced by bone resorption and 
formation, regulated to maintain of bone quality (Blair, 1998). Bone resorption and formation are 
linked closely within a temporary anatomic structures called the basic multicellular unit (BMU) 
which consists of a cutting cone formed by a group of osteoclasts, followed by a group of 
osteoblasts with form mineralizing connective tissue, i.e. bone in the closing cone (Figure 4, 
Parfitt 2002, Hernandez et al. 1999). The BMU exists and moves, excavating and refilling across 
the surface of trabecular bone as an instruments of bone remodeling. Osteoblasts regulate locally 
the differentiation and function of osteoclasts in normal bone. Bone remodelling comprises 
osteoclast-mediated bone resorption and osteoblast-mediated bone formation, which are regulated 
by hormones, growth factors and locally by cytokines (Raisz, 1999). Cytokines regulate their 
target cells via cell surface-bound cytokine receptors utilizing different intracellular signal 
transducing pathways (Klinger et al. 1998). Bone resorption occurs within the resorption site, 
Howship’s lacuna, a tightly sealed zone between the ruffled border of the osteoclast and bone 
surface. Subsequently osteoclasts produce an acidic environment and collagenolytic acidic 
endoproteinases, in particular cathepsin K. 
 
Figure 4. BMU travels through the bone 
tissue. Wi, represents width of the BMU; 
R represents rate of progression, 
expressed in units of BMUs per square 
millimeter of tissue per day; FP 
represents formation period (days); EP 
represents erosion period (days). The tail 
represents the new formed osteon 
(modified from Hernandez et al.  1999) 
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 Cellular activity at the remodeling site proceeds in an activation-resorption-formation (ARF) 
cycles (Figure 5). Mature osteoclasts need to undergo activation to initiate this cycle (Väänänen et 
al. 2000). In response to bone deformation, fatigue-related microfracture or wear particles, a 
group of preosteoclasts are activated. These mononuclear cells attach to the bone via αvβ3 
integrins and fuse to form multinucleated osteoclasts via fusion molecules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The functional events relevant for osteolysis consist of osteoclast migration towards bone, 
followed by adherence to the bone surface, initiation of the resorptive process, dissolution of 
hydroxyapatite, degradation of organic collagen-rich matrix, transcellular removal of degradation 
products from the resorption lacuna, and finally return to the non-resorption stage. Osteoclast 
migration requires the formation of podosomes which are unique actin-based adhesion structures 
(Destaing et al. 2003). Peripheral podosomes fuse to form the actin ring that circles the osteoclast 
domain, where active bone resorption occurs (Lakkakorpi et al. 1993). αvβ3 integrin is essential to 
podosome rearrangement, actin ring formation and osteoclast polarization (Faccio et al. 2002). 
The activated osteoclast forms a tight junction and a ruffled border facing the bone surface 
(Teitelbaum 2000). These processes result in the formation of resorption pits (Everts et al. 2002). 
In this depression called Howship’s lacuna, proton pump function drops pH so that inorganic 
hydoxyapatite mineral matrix is dissolved and that the pH becomes optimal for cathepsin K-
mediated collagen degradation (Everts et al. 1992, Farina et al. 2002). 
 
 
Activation 
Resorption
Figure 5. ARF cycle. 
Formation 
 
Osteoclasts secrete both H+-ions and cathepsin K important for osteoclastic bone resorption. Blair 
and coworkers (1989) and Väänänen and coworkers (1990) were the first who showed that it was 
vacuolar- type proton ATPase in osteoclasts that was responsible for mineral dissolution. Protons 
were pumped into the resorption lacuna using vacuolar H+-adenosine triphosphatase (ATPase) 
localized in the ruffled border of osteoclasts so that osteoclasts are capable of generating acidosis 
to cause mineral dissolution necessary for bone resorption (Tuukkanen and Väänänen 1986, 
Väänänen et al. 1990). Cathepsin K, which has high proteolytic activity and localizes primarily in 
osteoclasts, is one of the few extracellular proteolytic enzymes capable of degrading collagen. 
Under low pH, cathepsin K exerts autocatalytic activation and collagenolytic activity (McQueney 
et al. 1997, Konttinen et al. 2001). The secreted form of cathepsin K may be a proenzyme, but in 
the extracellular environment outside the osteoclasts it can be autocatalytically activated (Claveau 
et al. 2000). Overexpression of cathepsin K has been reported to increase bone destruction, while 
in cathepsin K deficienct mice, the bone resorption was impaired (Kiviranta et al. 2001, 2005). 
Therefore, in bone destruction process osteoclasts dissove mineral by acid environment and 
degrade uncalcified organic matrix by cathepsin K or MMPs (Syggelos et al. 2001, Garnero et al. 
1998). All the bone resorption byproducts are removed via transcytosis from the ruffled border 
facing to the bone to the other side of osteoclast to the extrcellular space. (Salo et al. 1997, Nesbitt 
and Horton 1997, Mulari et al. 2003). Gap junction may also regulate osteoclast function by 
 24
 regulating bone resorption, osteoclast survival and apoptosis (Ilvesaro and Tuukkanen 2003). 
Fibroblasts grow on bone surface during peri-implant osteolysis where they may cause bone 
dissolution by a similar mechanism by secreting H+ ions, but not forming resorptive 
compartments like osteoclasts do. Therefore, fibroblasts in the local environment of peri-implant 
can cause degradation of the bone surface by lowering the pH and releasing enzymes, but the 
amount of resorption is minor so the contribution of the process to the peri-implant bone lysis may 
be small (Pap et al. 2003). 
 
5. 5. 2 Collagen degradation 
 
Collagens are major structural proteins in the extracellular matrix, with more than 20 different 
types. Tissues contain 3 types of collagens: 1) soluble (monomers); 2) collagenase-cleaved 
collagen in fibers; can be solublized with chymotrypsin; 3) intact collagen in fibers, this is the 
insoluble matrix. Bone is connective tissue, which contains type I collagen fibers embedded in an 
inorganic hydroxyapatite [Ca10(PO4)6(OH)2] matrix. Type I collagen is among the most abundant 
proteins in the body. It accounts for up to 90% of the dry weight of bone and it is also the major 
matrix protein of tendons, ligaments, and soft connective tissues. All collagens have common 
conformation, the mature alpha chain and a triple helical collagen monomer contains 1000 of 
amino acids. Glycine has to be located at every third residue of the triplet amino acid sequence to 
allow helix formation. This is enabled as the side chain glycine is the simplest and smallest. These 
Gly-X-Y amino acid triplets, in which the “X” position is frequently occupied by proline and the 
“Y” position by hydroxyproline residues, form a single α-chain, which is the smallest structural 
unit of collagen. Three α-chains form a triple helical collagen monomer. These collagen 
monomers align into a nearly three-quarter-overlapping collagen fiber, which is stabilized through 
intermolecular cross-links. These fibers form the collagen bundles and networks in tissues 
(Persikov and Brodsky, 2002). Collagen fiber matrix is winding into natural bone fixed by HAP 
(Ca10(PO4)6(OH)2). The elastic modulus of bone is intermediate between hydroxyapatite and 
collagen (Fratzl et al. 1998). 
 
Two types of collagen degradation pathways have been discovered. One is the intracellular route 
mainly active in a physiological steady state and the other is extracellular route playing a major 
role in collagen matrix remodelling and various pathological conditions (Trackman et al. 2005). 
Collagenases play an important role in physiologic tissue remodeling and pathologic conditions. 
Imbalance of proteinases and their endogenous inhibitors may cause pathological collagen 
degradation. Once activated, osteoclasts secrete protons and proteinases at their attachment site, 
resulting in dissolution of bone mineral and degradation of the exposed collagen matrix in an 
acidic pH. Cathepsin K is probably the most important proteinases in this process (Konttinen et al. 
2001). The presence of various collagenases and cathepsin K in the synovial membrane-like 
interface membrane is necessary for collagen degradation. Collagen destruction in interface 
membrane might be mechanically induced by the micromovement subjected to cyclic loading or 
walking, in part due to unisoelasticity of the implant and host bone (Konttinen et al. 2005). High 
mechanical loading leads to an increased collagenase-1 (MMP-1) production (Holliday et al. 
1997). MMP-1 can only cleave collagen triple helix at the initial specific cleavage site between 
Gly775-Leu/Ile776 of the triple helix and acts as the rate-limiting enzyme in collagen proteolysis 
(Pardo et al. 2005). MMP-13 effectively degrades type II collagen and cleave type I collagen at an 
additional aminotelopeptide locus (Krane et al. 1996). It has been shown that MMP-1 and -13 
increased in aseptic loosening (Takei et al. 2000, Syggelos et al. 2001). Macrophages produce 
most MMPs in prosthetic interface tissue (Hembry et al. 1995), though fibroblasts also participate 
(Takagi et al. 1998). Under low pH cathepsin K is able to catalyze collagenolysis (Garnero et al. 
1998). Cathepsin K has both an intracellular lysosomal function and an extracellular function in 
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 the degradation of collagen (Kafienah et al. 1998). It is preferentially and highly expressed in 
osteoclasts and its level increases upon osteoclast activation (Corisdeo et al. 2001). Cathepsin K is 
able to hydrolyze type I collagen and to cleave across the collagen triple helix (Drake et al. 1996). 
All these enzymes can potentially participate in pathological peri-prosthetic bone destruction and 
act in concert with each other.  
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 6. AIMS OF THE STUDY 
 
Our hypotheses are: 
 
1) ADAM9 and ADAM12 particpate in the formation of foreign body giant cells and osteoclasts 
in aseptic loosening. The formation of foreign body giant cells and osteoclasts occurs in the 
interface tissue, which is always formed between the implant and host bone in the association to 
aseptic loosening. Therefore, their expression should be increased in aseptic loosening compared 
to control synovial membrane. 
 
2) We have earlier shown that peri-implant interface membrane contains several proteinases. We 
therefore thought that some of them could participate in the pathological collagenous tissue 
degradation in peri-implant tissues leading to an expanded joint space and implant loosening. 
 
Specific aims of the research: 
 
1) To study the regulation of selected markers and active substances in interface membrane 
around loosening hip implant together with in vitro studies using M-CSF and RANKL to 
stimulate cells in monocyte/macrophage lineage for cell-cell fusion. Molecules which 
were analysed are tentative fusion molecules (members in the ADAM family, namely 
ADAM8, ADAM9 and ADAM12). 
 
2) To use a new method to assess the degree of collagen degradation and to determine if 
collagen indeed is degraded around loosening hip implants and which proteinases are 
associated with this degradation. 
 
3) To develop a new parainfluensa virus type 2-driven model to study the expression and 
involvement of ADAM8, ADAM9 and ADAM12 in multinuclear giant cell fusion. 
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 7. MATERIALS AND METHODS 
 
7. 1 Tissue samples 
 
Synovial membrane-like interface tissue was collected from areas adjacent to osteolytic lesions 
from 7 females and 3 males undergoing revision THR due to aseptic loosening of prostheses. 
These ten samples were collected from the proximal bone-cement or bone-stem interfaces around 
femoral stems during revision THR operations (Fig 6. Grüen Zones 1 and 7; Grüen et al. 1979, 
DeLee et al. 1976). All patients suffered from aseptic loosening reported having hip/thigh pain 
and radiographs disclosed liner periprosthetic osteolysis. There were no major iatrogenic technical 
 
 
 
Figure 6. X-ray picture of a loose total hip prosthesis and surgical zones around the implant.  
 
problems such as femoral malalignment or poor cement mantle present in our patients, which 
could have explained loosening. The patients did not have any clinical signs or laboratory 
findings, which would have indicated deep joint infection. The type of implant material used in all 
patients was cobalt alloy-based prothesis. Nine patiens were fixed with cement, while only one 
was uncemented. None of the patients had severe metallosis. Their mean age was 71 years (range 
57-80 yr). Seven operations had been performed due to osteoarthritis, two for a sequeale of hip 
fracture and one secondary osteoarthritis caused by rheumatoid arthritis. Cefuroxime 1.5 gr was 
given intravenously 30-45 minutes before skin incision as a prophylaxis. In all revisions, three 
intraoperative cultures for aerobic organisms of joint fluid and interface tissues were obtainded 
and they were negative. The mean time from primary to revision THR was 7.7 years (range 5-16 
yr). Ten samples were obtained for comparison from patients undergoing primary THR performed 
for osteoarthritis. Seven of these patients were women and three were men. Their mean age was 
62.5 years (range 47–67 yr). Another set of nine control synovial membrane samples were 
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 obtained from hip fracture patients. Of these patients six were women and three men, with the 
mean age 67.4 years (range 39-89 yr). All samples were immediately immersed in physiological 
saline. Samples were snap frozen, embedded in Tissue-Tek OCT compound and stored at –70°C. 
Half of the sample was processed to paraffin after fixation in 4% formalin for 24 hours at room 
temperature followed by dehydration at room temperature, clearing and embedding in paraffin at 
55°C. All samples were analyzed using immunohistochemistry, five representative samples from 
revision and primary THR operations were also used for in situ hybridization, in addition tissues 
from three patients in each category were extracted and analysed using western blotting. 
 
7. 2 Cell culture 
 
7. 2. 1 Osteoclast formation assay 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats of three healthy 
blood donors of the Finnish Red Cross using Ficoll–Paque PLUS (Pharmacia Biotech, Uppsala, 
Sweden) density gradient isolation at 2500 g for 20 minutes at room temperature. Washed cells (1 
x 107/well) were incubated in six-well plates with or without coverslips in 2 ml of minimal 
essential medium (MEM, HaartBio Ltd. Helsinki, Finland) Alpha Medium with Glutamax-1 
(Invitrogen, San Diego, USA) supplemented with 10% fetal calf serum, 100 IU/ml of penicillin 
(Invitrogen) and 100 µg/ml of streptomycin (Invitrogen). After one hour, the non-adherent 
lymphocytes were washed away; the adherent monocytes were used for experiments and and they 
were stimulated with 25 ng/ml of rhM-CSF (R&D, Minneapolis, USA) and 40 ng/ml of 
rhRANKL (Alexis, Carlsbad, CA, USA, Paloneva et al. 2003) for 1, 3 7 and 14 days before they 
were analysed using immunofluorescence staining and flow cytometry. The media was replaced 
twice a week. 
 
7. 2. 2 Viral infection of GMK, HSG and HSY cells 
 
GMK, a kidney-derived epithelial-like cell line, is susceptible to PIV2 and was maintained in 
virological laboratories to generate PIV2 virions. It was obtained from the Helsinki University 
Central Hospital (HUCH) laboratory and maintained in minimal essential medium (MEM, 
HaartBio Ltd. Helsinki, Finland) containing 10 % (v/v) heat-inactivated foetal bovine serum and 
2.2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (HaartBio) in 75 cm2 culture 
flasks at 37°C and 5 % in the CO2 -incubator (Ammendolia et al., 2007). 
 
HSG cell line derived from human submandibular gland (Shirasuna et al., 1981) and HSY cell line 
derived from human parotid gland (Yanagawa et al., 1986) were cultured at 37°C, 5 % CO2-in-air 
in Dulbecco’s modified Eagle’s medium with nutrient mixture F-12 Ham (DMEM/F-12, Sigma, 
St. Louis, USA) supplemented with 10 % (v/v) fetal calf serum, 2.2 mM glutamine, 100 U/ml 
penicillin and 100 μg/ml streptomycin. 
 
PIV2 was obtained from the Helsinki University Central Hospital (HUCH) laboratory where it 
was used as a reference virus. The virus was grown in the GMK cells according to standard 
procedures (Richman et al., 1997). Medium was removed when the adherent GMK, HSG or HSY 
target cell cultures covered 70–90 % of the surface available for them in 75 cm2 cell culture 
flasks. Cultures were washed with 1 ml of culture medium twice and then exposed to 1.5 μg/ml 
trypsin solution at +37°C and in 5% CO2 for 5 minutes. The detached GMK, HSG or HSY cells 
were divided into 6-well plates, 1.2x106 cells per well. 23 µl PIV2 primary viral suspension, 
containing 2.7x107 infective units/ml per millilitre, was added to each 2.5 ml in cell culture well. 
The cells were harvested at 0 (before PIV2 was added), 2, 24 and 72 hours. In parallel, cells 
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 cultured without PIV2 were harvested as controls at same time points as above. 
  
7. 3 Immunohistochemistry 
 
7. 3. 1 Immunohistochemical avidin-biotin-peroxidase complex staining 
 
Ten consecutive 6 μm-thick cryostat sections were cut from each sample. The first and last 
sections were stained with hematoxylin-eosin to check the morphology, whereas the rest of the 
sections were used for immunohistochemistry. Sections were mounted on Dako TechMate 
capillary microscope slides (TechMateTM, Dako, Glostrup, Denmark) and fixed in 4°C acetone for 
15 minutes. Slides were washed in Dako ChemMate washing buffer and installed in a Dako 
TechMate Horizon immunostainer. Paraffin tissue sections were deparaffinized in xylene, 
rehydrated through a graded ethanol series and washed in 10 mM phosphate-buffered 150 mM 
saline, pH 7.4 (PBS). Antigens were retrieved for 30 minutes using MicroMED T/T Mega 
Laboratory Microwave Systems (Milestone, Sorisole, Italy) in 0.01 M sodium citrate buffer, pH 
6.0, using the AR98C S30M program. After blocking intrinsic peroxidase activity in 0.3% H2O2 in 
methanol for 30 minutes, The sections were incubated at 22°C as follows: (1) with 1:50 dilution of 
different normal serums: goat, rabbit or donkey (Jackson ImmunoResearch Laboratories, West 
Grove, USA) in phosphate buffer containing 0.1% bovine serum albumin (Sigma) for 30 minutes 
(2) the primary antibody (table 3), (3) biotinylated secondary antibody (table 3) and (4) avidin-
biotin-peroxidase complex. The sites of peroxidase binding were revealed by incubation in 
0.006% H2O2 and 3, 3'-diaminobenzidine tetrahydrochloride (DAB, Sigma) at 22°C for 1 to 10 
minutes in darkness. One of the sections on each slide was counterstained with Harris 
hematoxylin for one minute. The sections were dehydrated in a graded ethanol series, cleared in 
xylene, and mounted in synthetic mounting medium (Diatex, Becker Industrifärg AB, Märsta, 
Sweden). 
 
Purified nonimmune normal IgG or nomal monoclonal IgGs (e. g. IgG1 or IgG2a) of the same 
subtype but with irrelevant specificity was used instead of and at the same concentration as the 
primary antibodies as a negative staining control. Three osteoclastoma samples served as positive 
controls in staining (kindly provided by Dr. Mika Hukkanen). Both the negative staining and 
positive sample controls confirmed the specificity of immunohistochemical staining results. 
 
 7. 3. 2 Indirect immunofluorescence staining 
 
PBMCs cultured on coverslips for 1, 3, 7, or 14 days with or without rhM-CSF and rhRANKL 
were washed, fixed in 3% paraformaldehyde in PBS for 20 minutes, and incubated in: (1) the 
primary antibody (table 3) or as a negative control with purified normal IgG for 30 minutes; and 
(2) immunofluorescens, fluorescein isothiocyanate (FITC) or tetramethyl rhodamine isothiocynate 
(TRITC) conjugated secondary antibody (table 3) for 30 minutes. Nuclei were stained for 5 
minutes in 5 µg/ml of 4', 6-diamidino-2-phenylindole (DAPI) before mounting. 
 
7. 3. 3 Immunofluorescence double staining 
 
After deparaffinization 6 µm thick tissue sections were incubated for 30 minutes in 0.01 M 
antigen retrieval sodium citrate buffer, pH 6.0, in MicroMED T/T Mega Laboratory Microwave 
Systems (Milestone) using the AR98C S30M program. Nonspecific binding sites of were blocked 
with normal goat, rabbit or donkey serum followed by incubation in: (1) a mixture primary 
antibody (table 3) and CD68 (as a monocyte/macrophage marker), overnight at 4°C; and (2) a 
mixture of FITC conjugated and TRITC conjugated Secondary antibodies (table 3) for one hour at 
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 22°C. Purified normal goat or rabbit IgG at the same concentration as and instead of the specific 
primary antibodies was used as the negative staining control. All incubations were done at 22°C if 
not otherwise stated. Slides were air-dried and mounted in Vectashield (Vector, Burlingame, 
USA) and kept in the dark at 4°C. 
 
For PIV2 infection, cells were cultured on coverslips for 2, 24 or 72 hours, washed in PBS, fixed 
in acetone for 20 minutes at -20°C and incubated in 1) a mixture of ADAM8, 9 or 12 antibody 
with FITC-conjugated monoclonal mouse anti-parainfluenza 2 (Chemicon, Temecula, USA) for 
30 minutes and 2) immunofluorescence-labeled secondary goat anti-rabbit or donkey anti-goat 
antibody for 30 minutes. Coverslips were mounted in Vectashield Mounting Medium containing 
4', 6-diamidino-2-phenylindole (DAPI, Vector). 
 
Table 4. Primary antibodies of this study and some of their characteristics 
 
Molecule Description Source Manufacturer Concen
tration 
(µg/ml) 
Secondary 
antibodies 
Article 
hADAM8 Affinity 
purified  
Rabbit Cedarlane Lab, 
Hornby, Ontario, 
Canada 
1 Alexa Fluor 594-
labeled goat anti-
rabbit IgG 
IV 
hADAM9 Affinity 
purified, 
polyclonal 
Rabbit Triple Point Biologics, 
Forest Grove, USA 
1 Biotinylated goat 
anti-rabbit IgG 
II 
hADAM12 Affinity 
purified, 
polyclonal,  
Goat Santa Cruz 
Biotechnology, Santa 
Cruz, USA 
1 Biotinylated rabbit 
anti-goat IgG 
I 
hADAM12 Polyclonal 
antiserum 
Rabbit Gift from Dr. Ulla M. 
Wewer  
1 Alexa Fluor 488-
conjugated goat 
anti-rabbit IgG 
I 
hCathepsin 
K 
Affinity 
purified, 
polyclonal 
Goat Santa Cruz 1 Biotinylated rabbit 
anti-goat IgG 
III 
hCD68 Monoclonal
IgG1  
 
Mouse NeoMarkers, 
Freemont, CA, 
USA 
0.1–
0.5 
TRITC- conjugated 
donkey anti-mouse 
IgG 
 
I, II 
hM-CSF Affinity 
purified,  
Mouse  Biogenesis, Poole, UK 1 Biotinylated horse 
anti-mouse IgG 
I 
hMMP-1 Monoclonal 
IgG2aκ
Mouse Chemicon, Temecula, 
USA 
0.2 Biotinylated horse 
anti-mouse IgG 
III 
hMMP-13 Monoclonal 
IgG1κ
Mouse Chemicon 0.04 Biotinylated horse 
anti-mouse IgG 
III 
hRANKL Monoclonal 
IgG2b
Mouse R&D 1 Biotinylated rabbit 
anti-goat IgG 
I 
  
7. 4 In situ hybridizasion (ISH) 
 
Messenger RNA was isolated from total RNA. cDNA was synthesized using reverse transcriptase 
and oligo (dT)12-18. The primers were as follows ADAM 12: Sense 5’- ACA ATG CGC AGC 
TTG TCA GT -3’; Antisense 5’- TGA TGC AGC CTC CTT TCT CA –3’; ADAM9: Sense 5’- 
GCA TTT GTG GGA ACA GTG TG -3’; Antisense 5’- CCA GCG TCC ACC AAC TTA TT –
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 3’. Sequence similarities were searched using the NCBI Blast 2 program. Polymerase chain 
reaction (PCR) amplification of 5 ng cDNA samples was performed using 0.4 µM target-specific 
primers, AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA), and a 
thermal cycler (RoboCycler 40; Stratagene, La Jolla, USA) for 40 cycles. The identity of the 
product was verified by sequencing (QIAquick; Qiagen, Valencia, USA) using an automated 
Applied Biosystems 373A sequencer (Applied Biosystems). The PCR products were cloned using 
the TOPO TA cloning kit (Invitrogen). After purifying the recombinant vector using a NucleoSpin 
plasmid kit (Macherey-Nagel, Düren, Germany), the automated sequencer verified the orientation 
of the acquired antisense and sense sequences using M13 reverse or forward primers. After 
linearizing the plasmid using restriction enzymes Not I or Hind III, DNA templates were 
transcribed to 237 bp single-strand antisense RNA probe using SP6 RNA polymerase or a sense 
RNA control probe using T7 RNA polymerase. RNA was labeled using digoxigenin-conjugated 
UTP (DIG RNA labeling kit; Roche Diagnostics GmbH, Mannheim, Germany). A dilution series 
of digoxigenin-labeled RNA applied to nitrocellulose membrane confirmed the efficiency of RNA 
labeling. 
 
Frozen tissue sections were fixed in 4% paraformaldehyde at 4°C for 15 minutes, permeabilized 
for 30 minutes at 37°C in 100 mM Tris–HCl, 50 mM EDTA, pH 8.0, containing 5 µg/ml RNase-
free proteinase K, and dipped in 0.1 M triethanolamine diluted 1:400 (v/v) in acetic anhydride, pH 
8.0. To block non-specific hybridization, sections were prehybridized with hybridization buffer 
containing 100 µg/ml denatured salmon sperm DNA for one hour at 57°C in humidified chambers. 
After blocking sections were hybridized with 1–2 ng/µl digoxigenin-labelled RNA probe in 
humidified chambers at 57°C overnight. Following stringent post-hybridization washes, single-
stranded (unbound) RNA probe was degraded at 37°C for 30 minutes using 20 µg/ml RNase-A 
(Roche). Sections were blocked in normal sheep serum at 4°C overnight. Alkaline phosphatase-
conjugated sheep anti-digoxigenin-Fab (Roche) was added and colour was developed using 5-
bromo-4-chloro-3-indolylphosphate (BCIP; Promega, Madison, USA) substrate and nitroblue 
tetrazolium (NBT; Promega) colour. 1 % methylene green was used as a counterstain before 
mounting. 
 
7. 5 Polymethylmethacrylate particle uptake 
 
Using 500-grid SiC paper, polymethylmethacrylate (PMMA, bone cement) particles containing 
BaSO4 were produced from a PMMA block. These particles were preserved in a concentration of 
1.3 mg/ml in 99.5% ethanol until use in cell stimulation experiments. The diameter of the particles 
was 0.6–2 µm characterized using a NICOMPTM 370 (Particle Sizer Systems, Santa Barbara,  
USA) submicron particle sizer based on dynamic light scattering using particles suspended in 
solvent. Before stimulation, PMMA particles were sonicated using ultrasound for dispersal and 
cleaning with a Vibra CellTM processor (Sonics & Materials, Newtown, USA) with 2 second 
intervals (amplitude 80%, output 150 watts). Adherent monocytes were stimulated for 24 or 72 
hours using 25 ng/ml of rhM-CSF alone or together with 40 ng/ml of rhRANKL in the presence or 
absence of 1 x 106/ml PMMA particles. Non-stimulated resting cells were used as a control. 
 
7. 6 Bone resorption assay 
 
In vitro bone resorption assay was performed first using PBMCs stimulated with M-CSF and 
RANKL for 7 days to induce osteoclast differentiation (see 7.2.1). Then cells were detached with 
trypsin treatment followed by gentle scraping and transferred to 12-well plates containing dentine 
slice (size 5 x 5 mmm, Immunodiaonostic System, Boldon, UK) at the cell density of 4x105 / 
dentine slice. After seven days incubation with M-CSF and RANKL, the cells were brushed away 
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 and the resorption pits were visualized with toluidine blue. Samples were inspected using a Leica 
TCS SP2 confocal microscope (detailed in Konttinen et al. 2001). 
 
7. 7 Western blotting 
 
Tissue samples were homogenized in an ice-bath using sonication (Vibra-Cell 501; Sonics & 
Materials, Danbury, CT, USA) in RIPA buffer (RIPA buffer set; Boehringer Mannheim, 
Indianapolis, USA) for 15 seconds and centrifuged at 21 000 g for 3 hours at 4°C. Before 
electrophoresis, the total protein of the sample was quantified using the Bio-Rad Protein Assay 
(Bio-Rad Laboratories, Richmond, USA). Samples were boiled in sodium dodecyl sulphate (SDS) 
sample buffer (187.5 mM Tris HCl, pH 6.8, 6 % SDS, 30 % glycerol, 0.03 % phenol red, and 125 
mM dithiothreitol, diluted 1:3; New England Biolabs, Beverly, USA) and adjusted to 100 µg per 
lane. After 10% SDS–polyacrylamide gel electrophoresis, the gels were equilibrated and blotted 
onto nitrocellulose membrane (Bio-Rad Laboratories). The membranes were incubated at room 
temperature in (1) 3% bovine serum albumin (Sigma) in Tris-buffered saline blocking solution 
overnight, (2) the primary antibody (table 3) for 60 minutes, and (3) alkaline phosphatase-
conjugated secondary antibody (Bio-Rad Laboratories) for 60 minutes. Between the steps, the 
membranes were washed in 0.1% Tween 20 in 50 mM Tris, 0.9% NaCl, pH 7.5 (Tris-buffered 
saline). Colour reaction was developed for 15 minutes using BCIP and NBT (Alkaline 
Phosphatase Conjugate Substrate Kit, Bio-Rad Laboratories). 
 
Human peripheral blood monocytes were costimulated with rhM-CSF and rhRANKL for 1, 3, 7, 
or 14 days in 6-well plates and then lysed with 200 µl Passive Lysis Buffer (Promega). Cell debris 
was removed by centrifugation at 10,000 g for 10 minutes at 4°C and supernatant was stored at –
70°C. Before electrophoresis, the total protein of the sample was quantified using Bio-Rad protein 
assay (Bio-Rad Laboratories), the sample was boiled in SDS containing sample buffer (New 
England Biolabs) at 98°C for 5 min and 75 µg protein was loaded per lane. After SDS-
polyacrylamide gel electrophoresis, samples were blotted onto nitrocellulose membrane (Bio-
Rad). Membranes were stained at room temperature as mentioned above. 
 
7. 8 Flow cytometry of monocyte/macrophages 
 
Adherent cells were stimulated either for 24 h or 72 h using 25 ng/ml rhM-CSF (R&D) alone or 
together with 40 ng/ml rhRANKL (Alexis) in the presence or absence of 1 x 106/ml PMMA 
particles. They were gently scraped and fixed with 4% w/v paraformaldehyde for 30 minutes at 
4°C and permeabilized with Perm/Wash buffer (Becton Dickinson, San Jose, CA). 2 x 105 cells 
were incubated in (1) the primary antibody/antibodies (table 3) at 4°C for 60 minutes. (2) 
incubated for 60 minutes in dark with immunofluorescence conjugated secondary 
antibody/antibodies (table 3). The stained cells were analysed with a FACScan analyser using 
CellQuest software (Becton Dickinson). The level of non-specific binding was determined using 
isotype-matched antibodies of irrelevant specificity. 
 
7. 9 Measurement of degraded collagens in tissues 
 
Degraded collagen was measured as described in detail elsewhere (Bank et al. 1997). Briefly, 
tissue block around 3 x 3 x 2 mm was incubated with 4 M guanidium chloride-hydrochloric acid 
in incubation buffer of 0.1 M Tris-HCl, pH 7.3 containing 1mM iodoacetamide, 1 mM EDTA and 
10 μg/ml pepstatin-A for 48 hours at 4°C to remove proteoglycans. After washing with incubation 
buffer 3 times for 3-6 hours at 4°C, followed by incubation in 1 mg/ml α-chymotrypsin to digest 
denatured collagen in the insoluble matrix. After hydrolyzing the supernatant and pellet in 6 N 
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 HCl at 110°C for 20-24 hours, the hydrolyzates were dried overnight and to residue HCl, sample 
were reconstituted with distilled water and dried again. Finnally, the samples were dissolved in 1 
ml of 0.1 M borate buffer, pH 9.5 undiluted for supernatant (hydrolyzates of supernatants) or 
diluted 1:250 for non-soluble matrix (hydrolyzates of pellet) ready for amino acid analysis. 
 
200 μl samples were mixed with 25 μl 30 mg/ml o-phthaldialdehyde containing acetone and 1.5 % 
(v/v) β-mercaptoethanol for one minute at room temperature. 25 μl of 80 mg/ml iodoacetamide in 
acetone was added for at least 30 seconds at room temperature to remove excess β-
mercaptoethanol by precipitation. After derivatization with 9-fluorenylmethyl chloroformate, 
hydroxyproline and proline were extracted with diethyl ether and dissolved in solvent A (20 mM 
sodium citrate containing 5 mM tetramethylammonium chloride and 0.01 % NaN3, pH 2.85). 
Elution was performed in two isocratic steps using 60 % and 25 % solvent A with 40 % and 75 % 
solvent B (acetonitrile) with 1 ml/min flow rate, on-line monitoring at excitation wavelength of 
254 nm and emission wavelength of 630 nm at room temperature. The percentage of total 
collagen present in tissue was calculated and desribed as the amount of degraded collagen. 
degraded collagen % = hydroxyproline content in supernatant digested by α-chymotrypsin × 
100% / (hydroxyproline content in supernatant digested with α-chymytrypsin + hydroxyproline 
content of digested plug). 
 
7. 10 Image analyse  
 
Specimens were inspected using 200 x magnification and Leitz Diaplan- microscope (Leitz, 
Wetzlar, Germany) or Olympus motorized revolving AX 70 system microscope, which is coupled 
to 12-bit PC digitalcamera (SensiCam, Kelheim, Germany). Pictures were analysed 
semiautomatically using AnalySIS Pro 3.2 Image analys- and processing datasystem (Soft 
Analysis System GmbH, Münster, Germany). The images were analyzed morphometrically after 
adjusting illumination and focus. The whole section area was analyzed. The results of quantitative 
assessment are expressed as percentage of positively staining area of the total tissue area. 
 
7. 11 Statistical analysis 
 
The results are mainly expressed as mean and standard error of the mean (SEM). Some data 
expressed as range and median value. Wilk's W test was performed for checking normality of all 
data. The t-test was performed for normally distributed data between groups, while Wilcoxon's 
test for skewed data. Probability values less than 0.05 were considered statistically significant. 
These statistical calculations were done using statistical software BMDP-PC version 7.01 (BMDP 
Statistical Software, Cork, Ireland). 
 
7. 12 Ethical aspects  
 
The work had been accepted by the ethical committee Helsinki University Hospital (HUS). 
Helsinki and Vancouver declarations were followed. 
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 8. RESULTS  
 
8. 1 M-CSF and RANKL in interface membrane 
 
Immunohistochemical analysis revealed intense M-CSF and RANKL immunoreactivity in many 
cells of the synovial membrane-like interface membrane around loosened THR implants. M-CSF 
was mostly found in macrophage-like cells and multinuclear giant cells, which often contained 
phagocytosed cytoplasmic foreign bodies, whereas RANKL was found both in fibroblast- and 
macrophage-like cells. In contrast to the relatively extensive and strong immunoreactivity in 
revision total hip replacement samples, M-CSF and RANKL containing cells were relatively few 
and staining was weak in control synovial membranes obtained from primary total hip 
replacements. For practical and ethical reasons it is not easy to obtain implant capsule tissue 
control samples from well-fixed total hip implants, although occassionally well fixed implants are 
revised because of periprosthetic fracture or mechanical failure including dislocations, 
malpositions and instability, etc. The absence of appropriate control samples is one of the 
limitations of these studies. In this study, we used synovial membrane obtained from patients with 
osteoarthritis undergoing primary THR as control tissue, because inflammation in such tissue is 
often mild or minimal. Traumatic synovial membrane would probably have been an even better 
control. However, the clear difference between interface membrane and membrane from 
osteoarthritis membrane clearly suggests an active role for M-CSF and RANKL in aseptic 
loosening. Negative staining controls were negative and confirmed the specificity of the staining. 
 
8.2 ADAMs expression and osteoclast formation  
 
8. 2. 1 ADAM9 and ADAM12 in interface tissue 
 
Several ADAM12 positive cells were detected in synovial membrane-like interface tissue, 
whereas fibrous area filled with collagen fibers and fibroblast-like cells did not stain for 
ADAM12. Blood vessels occasionally stained for ADAM12. All multinuclear foreign body giant 
cells were ADAM12 positive. In double immunofluorescence staining, CD68 marker used to 
detect macrophages and multinuclear giant cells in the synovial membrane-like interface tissue 
around loosened THR implants, all CD68 positive cells were also ADAM12 positive. In addition, 
mononuclear ADAM12 positive cells were often detected closely to multinuclear ADAM12 
positive cells. Negative staining controls and positive sample controls confirmed the staining 
results. Negative control experiments performed using consecutive sections did not show any 
labeling. In positive osteoclastoma sample controls (Tian et al. 2002) the percentage of ADAM12 
positive cells (74 ± 3%) ranks the highest, while osteoblasts, osteocytes, and chondrocytes were 
ADAM12 negative. Both macrophage-like and foreign-body giant cells were ADAM12 positive 
in the interface membrane, whereas control membranes contained only a few ADAM12 positive 
macrophage-like cells and no ADAM 12 positive foreign-body giant cells. Morphometrically, the 
comparison between the percentage of ADAM12 positive cells in revision THR and in primary 
THR samples was statistically significant (53 ± 2% vs. 5 ± 1%, p<0.001). Moreover, the intensity 
of cellular ADAM12 staining in revision THR samples was higher than in primary THR samples. 
 
Immunohistochemical staining was used to localize ADAM9 and its cellular sources in interface 
membrane tissue samples. The staining intensity varied in different samples and different regions. 
Intense ADAM9 immunoreactivity was detected in all synovial membrane-like peri-implant 
interface tissue samples around loosened implants. The inflammatory, cell-rich areas contained 
several ADAM9 positive macrophage-like cells, whereas such cells were much rarer in the deep 
fibrotic tissue areas which lack of ADAM9 positive signal. In particular, the synovial lining-like 
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 layer facing the pseudosynovial fluid always exhibited intense staining in interface tissue samples. 
All multinuclear foreign body giant cells were ADAM9 immunoreactive. Mononuclear ADAM9 
positive cells were often close to ADAM9 positive multinuclear cells or in small aggregates in 
intimate contact with each other. Cellular ADAM9 staining was stronger in revision THR than in 
control synovial membrane samples from the primary THR which exhibited weak 
immunoreactivity for ADAM9, and restricted to certain areas. The percentage area of ADAM9 
positive immnunoreactivity was measured because of some extracellular ADAM9 staining. The 
percentage of ADAM9 positive area in revision THR was different from that of the primary THR 
samples (37.6 ± 5.1% vs. 5.2 ± 0.8%, p=0.002). Staining controls produced by using purified non-
immunized rabbit IgG at the same concentration as and instead of specific primary anti-ADAM9 
IgG were almost totally negative. 
 
The total overlap between ADAM9 immunoreactivity with CD68 positive cells was disclosed 
using TRITC and FITC double staining. The close spatial relationships were found between 
ADAM9 positive mononuclear cells and ADAM9 positive multinuclear giant cells and also 
between CD68 positive mononuclear cells and CD68 positive multinuclear giant cells. All 
ADAM9 positive cells were also CD68 positive in interface tissue. In control osteoarthritic 
synovial membrane samples ADAM9 immunoreavtivity was usually weak and restricted to 
certain areas, while all CD68 positive macrophages were also ADAM9 positive in double 
staining. A 50 KDa band in the Western blots was ADAM9 immunoreactive in tissue extract 
samples of revision THR but was not found in samples from primary THRs. 
 
In situ hybridization demonstrated ADAM12 messenger RNA in macrophage-like cells and in 
multinuclear foreign body giant cells. Furthermore, the synovial lining-like layer and some blood 
vessels contained ADAM12 messenger RNA, whereas fibroblast-like cells were not labeled. Then 
in the consecutive tissue labeled using sense RNA probe showing negative labeling confirmed the 
specificity of the labeling. 
 
In situ hybridization of ADAM9 messenger RNA using DIG-labeled ADAM9 cRNA probe 
detected ADAM9 messenger RNA in macrophage-like cells and multinuclear giant cells. ADAM9 
messenger RNA was found in all synovial membrane-like interface tissue samples around 
loosened hip implants. The lining-like layers and macrophage-rich sublining areas showed strong 
signal, whereas ADAM9 transcript positive cells more rarely appeared in the deep stroma of the 
interface tissue samples. Similarly to immunostaining, ADAM9 messenger RNA positive 
mononuclear cells were often seen in close contact with ADAM9 mRNA positive multinuclear 
cells. The negative sense RNA probe in the consecutive tissue sections confirmed the specificity 
of the labeling. In tissue controls ADAM9 mRNA was weakly detected and restricted in synovial 
lining and sublining areas of the samples obtained from primary THR operations. This indicates 
ADAM9 transcripts much less in the controls. 
 
8. 2. 2 ADAMs in M-CSF and RANKL stimulated osteoclast formation assay 
 
Peripheral blood mononuclear cells stimulated with M-CSF and RANKL and adherent to 
coverslips were stained to analyze fusion process over time. Those cells which had not been 
stimulated with M-CSF and RANKL showed weak staining of ADAM9. One day after M-CSF 
and RANKL costimulation the ADAM9 staining was still weak. Cultured cells were large, but 
still mononuclear and ADAM9 expression was stronger compared to day 1, widespread and 
slightly granular at culture day 3. At culture day 7, several bi- or multinuclear cells had appeared 
and ADAM9 staining was quite strong. At culture day 14, most of ADAM9 positive cells were 
multinuclear giant cells and the percentage of mononuclear ADAM9 positive cells declined. 
 36
 ADAM9 staining showed strong and non-homogenous cytoplasmic granular patches. 
 
According to FACS analysis, all ADAM12 positive monocytes cultured for one day in the 
presence of M-CSF and RANKL were also CD14 positive. These FACS analysis results were 
similar to those of resting peripheral blood monocytes without M-CSF and RANKL stimulation. 
In vitro stimulation of peripheral blood monocytes with M-CSF and RANKL for a short one-day 
time did not seem to increase significantly the number of ADAM12 molecules per cell. At culture 
day 1, ADAM12 was detected usually as one cytoplasmic patch in M-CSF and RANKL 
costimulated human peripheral blood monocytes. At culture day 3, all cells were large, showing 
widespread cytoplasmic staining, but almost all cells were still mononuclear. At culture day 7, the 
cells were very large and began to fuse, showing several bi- and multinuclear cells with relatively 
strong cytoplasmic granular ADAM12 staining. At culture day 14, the the percentage of 
multinuclear giant cells increased, while the percentage of mononuclear cells decreased (Figure 
7). According to morphometric analysis, 26 % of the cells were binuclear and 12 % multinuclear 
at culture day 7 and 14 % of the cells were binuclear and 66 % multinuclear at culture day 14. 
These results imply that fusion started at day 3. When transferred to dentin slices at culture day 7 
and cultured for seven additional days, these cells at day 14 had formed resorption pits indicating 
the capability of bone resorption in vitro as shown before (Mandelin et al. 2005). 
 
Figure 7. M-CSF and RANKL costimulated 
human monocytes during the first (A and B), third 
(C and D), seventh (E and F) and fourteenth (G) 
culture day. The red color shows ADAM 12 and 
the blue presents DAPI- stained cell nuclei. 
 
 
 
 
 
 
 
 
 
As monocyte/macrophages are both adherent and long living cells, the analysis of ADAM 9 and 
ADAM 12 staining patterns over time could be performed using adherent cells cultured till 14 
days on coverslips. Human peripheral blood monocytes were enriched and stimulated with M-
CSF and RANKL in vitro to induce osteoclast-like cell formation. Such costimulation led to 
characteristic time-dependent phenotypical changes of the cell size, number of nuclei and ADAM 
staining pattern. These changes to a cytoplasmic granular staining pattern of the bi- and multi-
nuclear cells observed at days 3 and 7 of stimulation and further to even more extensive granular 
and patchy cytoplasmic staining pattern by day 14 in multinuclear cells. 
 
PBMCs were also cultured both in the presence and in the absence of PMMA particles were 
ADAM9 positive at day 1 according to flow cytometric analysis. At culture day 3, the ADAM9 
staining intensity increased with a clear change in staining over time, while non-stimulated resting 
cells were ADAM9 negative. With or without M-CSF and RANKL did not significantly affect the 
result of PMMA stimulation. 
 
Western blots of cell extracts were prepared from M-CSF and RANKL costimulated human 
peripheral blood monocyte cultures at culture day 1, 3, 7 and 14. The synthesis of the latent 90 kD 
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 ADAM12 had apparently increased upon the stimulation after 3 days of M-CSF and RANKL 
costimulation and remained high until the end of the 14-day culture. In addition to the increased 
expression, a weak 60 kD band was detected, most clearly in cells stimulated for 3 days. These 
studies demonstrated that the 60 kD ADAM band represents, as assessed by its immunoreactivity 
and size, metalloproteinase-cleaved, fusion-active ADAM 12. 
 
8. 2. 3 ADAMs in the PIV2 infected host cells 
 
At 2 hours, PIV2 antigens were not yet found in infected GMK cells and also ADAM8 and 
ADAM9 were negative (Figure 8, A, B). At culture day 1, PIV2 antigens were seen in infected 
GMK cells. In addition, infected and some uninfected GMK cells were ADAM9 positive (Figure 
8, C), but negative for ADAM8. At culture day 3 PIV2 had infected most GMK cells and had 
caused cytopathic effects so that large multinucleated syncytia were seen. Staining of ADAM9 
positive multinuclear giant cells was relatively strong (Figure 8, D) but no ADAM8 positive cells 
were seen. 
 
 
Figure 8 Immunofluorescence double staining of ADAM9 and PIV2 in PIV2 virus infected GMK 
cell cultures at day 0 (panel A, B), 1 (panel C) and 3 (panel D). ADAM9 staining is shown in red 
and PIV2 in green, together with the blue nuclear counterstain. At day 0, PIV2 antigens were not 
yet seen inside the cells (A) and ADAM9 staining was negative (B); (C, D) overlay of double 
staining of ADAM9 and PIV2 at culture day 1 and day 3, respectively. Bar = 10 μm.  
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 PIV2 were not detected in the HSG cell cultures in the presence with PIV2, so HSG cells were not 
infected PIV2 at not all. While PIV2 infected human HSY cells on coverslips were stained to 
analyze the cellular staining pattern during different time points of infection. The uninfected cells 
showed very weak ADAM8 signal. At culture day 0, PIV2 had not yet infected HSY cells and 
ADAM8 showed weak staining. At culture day 1, PIV2 was seen in HSY cells, where numbers of 
cytoplasmic patches of ADAM8. At culture day 3, PIV2 was seen in most HSY cells and the 
numbers of adherent cells were lower, because PIV2 infected and multinucleated cells were 
nonadherent. ADAM8 positive, multinuclear giant cells stained relatively strongly with a non-
homogenous granular and widespread patchy cytoplasmic staining. 
 
8. 3 Collagen degradation analysis 
 
Three different collagenolytic enzymes, MMP-1, MMP-13 and cathepsin K were examined both 
in the control synovial membrane from trauma patients and in the interface membrane around 
loosened total hip replacement implants (Table 5). The numbers of cells positive for all three 
proteins were higher in the interface membrane than in the control synovial membranes, as 
follows: MMP-1 (range 110-340, median value 325.5 vs. 48-80, median value 62), MMP-13 
(range 74-261 median value 139 vs. 12-52 value 23) and cathepsin K (range 58-157 median value 
119 vs. 5-23 median value 15). The approximate fold-differences of the positive cell numbers 
between patient and control are 5 folds for MMP-1, 5 folds for MMP-13 and 7 folds for cathepsin 
K. Compared to 9.2%-13% (median value 13%) degradation in control synovial membrane from 
traumatic patients, collagen in interface membrane around aseptically loosened totally replaced 
hip implants was degraded to 18%-34% (median value 21%). The correlations between collagen 
degradation and the number of cells expressing these proteinases were calculated. In aseptic 
loosening correlations with the degree of collagen degraded were for MMP-1 (r = 0.88, P = 
0.002), MMP-13 (r = 0.92, P = 0.001) and cathepsin K (r = 0.98, P < 0.001 ). In contrast, in 
normal synovial membrane these correlations were far from significant although MMP-1 come 
close to statical significant (r = 0.86, P = 0.062). The corresponding values for MMP-13 (r = 0.63, 
P = 0.26) and cathepsin K (r = 0.009, P = 0.99) were not significant. 
 
Table 5. Comparison of three collagenolytic enzymes in patient samples with controls 
 
 number of positive cells collagen degradation correlation 
 patient control patient controls patient controls 
MMP-1 110-340 
(median 325.5) 
48-80 
(median 62) 
r = 0.88 r = 0.86 
MMP-13 74-261 
(median 139) 
12-52 
(median 23) 
r = 0.92 r = 0.63 
Cathepsin K 58-157 
(median 119) 
5-23 
(median 15) 
 
18%-34% 
(median 21%) 
 
9.2%-13% 
(median 13%) 
r = 0.98 r = 0.009 
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9. DISCUSSION 
 
9. 1 ADAMs expression and osteoclast formation in interface tissue 
 
M-CSF was first described and purified from mouse yolk sac-conditioned medium (Johnson et al. 
1978), while RANKL was first found on the surface of activated T-cells (Anderson et al. 1997, 
Wong et al. 1997). It is known that the cytokine combination of M-CSF and RANKL is necessary 
to induce hematopoietic cells or monocytes to fuse to form morphological and functionally typical 
osteoclasts in vitro (Quinn et al. 1998). Therefore, we aimed to confirm the presence of both M-
CSF and RANKL in our revision samples. The presence of M-CSF and RANKL in interface 
tissue seems to confirm the molecular machinery able to induce and stimulate progenitor cell 
fusion to foreign body giant cells and osteoclasts which both are present at this scene of the 
aseptic loosening process. M-CSF and RANKL are also essential to podosome rearrangement and 
for the intracellular signaling pathway that induced cytoskeletal and motility changes in 
osteoclasts which lead to localized bone resoption and osteolysis (Pfaff and Jurdic 2001, Grey et 
al. 2000). 
 
Aseptic loosening of THR implant could be considered as macrophage-driven chronic 
inflammation or macrophage-driven synovitis, which is characterized by macrophage 
accumulation and activation. Because CD68-positive synovial tissue macrophages were all 
ADAM12 positive, as revealed using immunofluoresence double staining, and over half of the 
cells in the synovial membrane-like interface tissue were ADAM12 positive macrophage-like 
cells, compared to only 5 % in the corresponding control samples from osteoarthritic synovial 
membranes, these results showed how intense the local accumulation of macrophages is. 
Normally, monocytes transmigrate to the interface membrane from the circulation, but in foreign 
body reaction this might be amplified further by M-CSF which drive macrophages to proliferate 
locally. On the other hand, T-lymphocyte responses could be able to contribute to pathogenesis of 
aseptic loosening as has been suggested in particular for the metal-to-metal prosthesis (Weyand et 
al. 1998, Farber et al. 2001, Hallab et al. 2005). Metal ions are produced from electrochemical 
degradation (corrosion) which can as haptens bind to proteins making them allergens. However, 
the most frequently used prosthesis type is metal-to-UHMWPE, which produces mainly 
UHMWPE wear particles. Aseptic loosening of this type of prosthesis is often characterized by 
particle disease and macrophage dominance was demonstrated using ADAM12 labeling showing 
above. Metal-on-metal implants were not studied in these case series. 
 
Based on the results above, it is apparent that ADAM12 mRNA- and protein-positive 
mononuclear cells were often seen in close spatial relationship to each other. ADAMs has 
multipurpose domain structure consisting of the N-terminal end prodomain, which is followed by 
a metalloproteinase domain and a disintegrin domain. This is the origin for the name of this whole 
family of molecules. As a transmembrane molecule containing extracellular metalloproteinase 
domain ADAM12 represents cell membrane-associated proteolytic potential enabling cell-
mediated extracellular matrix remodeling (Le et al. 2003). This might contribute to 
monocyte/macrophage transmigration so that they can move to interface tissues. In accordance 
with this hypothesis, our results showed that all monocytes and macrophages seemed to be 
ADAM12-positive. The disintegrin domain of ADAM12 is involved in binding of integrin 
receptors, therefore, it might be involved in a non-RGD-dependent manner in cell–extracellular 
matrix and cell–cell attachment and signaling. Both cellular attachment and formation of 
polykaryons are important processes in aseptic loosening. Both M-CSF and RANKL are abundant  
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 in interface tissue as shown above. This could be impled that these two factors drive prefusion 
macrophages to form polykaryons with the help of ADAMs. 
 
After metalloproteinase and disintegrin domains in ADAM proteins follow the cysteine-rich 
domain and epidermal growth factor-like domain, which may be involved in some membrane 
fusion and cell fusion reactions (Becherer et al. 2003). The intracellular, cytoplasmic C-terminal 
tail is highly variable both in length and sequence. The interaction of the cytoplasmic domain of 
ADAM12 with intracellular actin cytoskeleton has the potential to control fusion process by 
transducing signals and by regulating the cytoskeleton (Cao et al. 2001). 
 
ADAM12 plays a role at multiple levels of cell-to-cell fusion process. Both the 
immunohistochemical staining results of the M-CSF and RANKL costimulated cultured human 
monocytes and Western blotting of cell extracts demonstrated the increased expression of the 
prodomain cleaved ADAM12, with an approximately molecular weight of 92 kD. However, the 
full length 92 kD ADAM12 can not catalyze fusion. This requires the removal of the 
metalloproteinase domain, which caps the full-length latent ADAM12 thus preventing these 
fusion-promoting activities (Schlomann et al. 2002, Yagami-Hiromasa et al. 1995). Quite 
corresponding with Western blotting of cell extracts, in particularly, at day 3 before the peak of 
cell fusion some of ADAM12 was found also in the 60 kD area. This band corresponds to the 
metalloproteinase-cleaved, fusion-active form of ADAM12 based on its molecular weight and its 
time of appearance. This time point just before the monocytes start to fuse and form 
multinucleated cells corresponds with the conversion of the full length ADAM12 into its 
metalloproteinase-cleaved 60 kD active form. This is also accordance with results from in vitro 
myogenesis studies in which ADAM12 mRNA increased before fusion and decreased during the 
completed cell fusion process. The progressive upregulation of the ADAM12 gene until day 8 in 
cultures of human peripheral blood monocytes undergoing fusion followed by a dramatic decrease 
of its mRNA expression at day 9 has been reported previously (Verrier et al. 2004). This suggests 
a role for ADAM12 in the early stage of the human osteoclast formation. 
 
Our study is the first to demonstrate a disintegrin and a metalloproteinase ADAM9 in the interface 
tissues of revision THR patients. Both macrophage-like and foreign body giant cells were 
ADAM9 positive in the interface membrane. Double immunofluorescence labelling of ADAM9 
and CD 68 revealed the expression of ADAM9 in all macrophages and monocytes. ADAM9 
positive mononuclear cells represent prefusion cells which locate in close contact with 
multinuclear cells. ADAM9 expression in revision THR tissues was also confirmed by Western 
blot analysis. However, the lack of ADAM9 band in Western blots of control synovium 
membrane samples is in a discrepancy with our immunohistochemical ADAM9 staining of such 
samples. This may be explained so that the ADAM9 concentration in the extracts remains below 
the detection level of the Western blot method while the staining still shows few positive cells. 
Immunohistochemistry can be used to show individual positive cells even among hundreds or 
thousands of other negative cells. 
 
ADAM9 has a complex and multifunctional domain structure and seems to play multiple roles 
during cell fusion. It contains a putative fusion peptide sequence, which like viral fusion peptides, 
may participate in membrane fusion via its cysteine-rich domain (Blobel et al. 1992). Some 
studies have investigated the fusogenic activity of this kind of synthetic peptides binding with 
liposomes (Martin et al. 2000). Further studies using overexpression or mutants of cysteine-rich 
domain would elucidate ADAM9 structure and function relate to the process of cell fusion. 
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 In both ADAM9 and ADAM12 studies, in interface membrane mRNA and protein positive 
mononuclear cells were often seen in a close spatial relationship to each other. As interface tissue 
was apparently also a rich source of M-CSF and RANKL, it is possible that these two factors 
drive prefusion macrophages to form polykaryons. Expression of ADAMs in both osteoclast 
precursors and mature osteoclasts indicates that these proteins are involved in cell fusion and 
osteoclast activity (Verrier et al. 2004). As fusion molecules, ADAM9 and ADAM12 overexpress 
in the trans-membrane when macrophages develop abundant interdigitations in their adjacent 
plasma membranes. Both ADAM9 and ADAM12 contain a stretch of hydrophobic amino acids, 
known as a fusion peptide, which penetrates adjacent cells to break the lipid bilayer of the cells. 
Then they undergo a conformational change and propel the plasma membrane close enough to 
trigger to open and fuse the membranes. Once fusion of the membrane structure has been initiated, 
the cytoplasms are integrated. Studies on the biochemical regulation and biological modulation of 
ADAMs are in progress. Intracellular, pericellular and gene level regulation control the activities 
of ADAMs. After cleavage of the prodomain by a furin-peptidase in the trans-Golgi, the mature 
form of human ADAM12 is stored intracellularly and has a potential to be translocated to the cell 
surface. It has been reported that protein kinase C epsilon induces ADAM12 translocation and 
expression to the cell surface (Sundberg et al. 2004). Both β1 and β3 integrins can bind to 
ADAM12 to regulate cell adhesion (Thodeti et al. 2005). ADAM9 expression has been shown to 
be regulated by intracellular reactive oxygen species and/or hydrogen peroxide which are 
generated in stressed cells (Sung et al. 2006). ADAM9 mRNA levels were downregulated upon 
treatment with interleukin-1α (Flannery et al. 1999). In interface tissue, the regulation of ADAM9 
and ADAM12 may be modulated by locally accumulated macrophages in response to wear 
particles. ADAMs are apparently multidomain, multipurpose molecules important for 
monocyte/macrophage function, including fusion of these cells to multinuclear foreign-body giant 
cells responding to wear debris and to the formation of osteoclasts resorbing peri-implant bone in 
aseptic loosening of total hip replacement. 
 
The virus-induced HSY cell fusion may represent cytopathic effect which is able to spread viral 
particles from infected cells to other infected or uninfected.cells Thus, this process shares some 
features with monocytes–macrophage forming multinuclear cells. In this study, we launched a 
new PIV-2 induced GMK cell and HSY cell fusion model to be able to characterize putative 
fusion molecules ADAM8 and ADAM9. Of these fusion molecules, ADAM9 was expressed in 
PIV-2 infected GMK cells and multinuclear giant cells, while ADAM8 was expressed in HSY 
cells and multinuclear giant cells. After several days of coculture with PIV-2, cytopathic effects 
were seen in form of formation of large multinucleated cells which showed poor adherence to the 
cell culture dish (Henrickson et al. 2003). Coculture with PIV-2 virus and infection of the GMK 
and HSY cells was accompanied by phenotypical changes of the cells, number of nuclei and 
ADAMs staining pattern. At culture day 0, PIV2 virus was not yet seen in either GMK or HSY 
cells and ADAM8 was only weakly expressed in HSY cells, while ADAM9 was negative in GMK 
cells. This was changed by culture day 1 as PIV2 antigen was seen both in GMK and HSY cells, 
and GMK cells showed ADAM9 positive and HSY cells showed cytoplasmic patches of ADAM8. 
At culture day 3, PIV-2 antigen was seen in most GMK and HSY cells and the formation of large 
multinucleated cells were induced so that the number of adherent cells decreased and both 
ADAMs staining was relatively strong with a non-homogenous granular and widespread patchy 
cytoplasmically staining pattern. These changes in ADAMs expression upon formation of 
polykaryons suggest that ADAMs may dynamically participate in the fusion process and the 
formation of multinuclear giant cells. This new model allows the characterizations of the 
molecular mechanism of the fusion proteins in the future. 
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 9. 2 Collagen degradation as part of osteoclast function 
 
This is the first study directly demonstrating the increased collagen degradation in the interface 
membrane of aseptic loosening compared to control synovial membrane from the patients with hip 
fracture. These measurements demonstrate enhanced remodelling and/or pathological collagen 
tissue destruction in interface tissue. As a synovial membrane-like interface membrane always 
surrounds failing implants, this interface has been considered to play a role in peri-implant tissue 
destruction and loosening. Interface tissue is characterized by non-autoimmune, 
monocyte/macrophages and fibroblasts dominated chronic foreign body inflammation (Atkins, et 
al. 1997, Goodman et al. 1998). It can be considered as a prototype of and an interesting model 
for foreign body inflammation and macrophage- and fibroblast-mediated synovitis (Hembry et al. 
1995). In aseptic loosening the monocyte/macrophage lineage cells are usually activated (Chun et 
al. 1999), but also metal hypersensitivity and lymphocyte-mediated responses have been observed 
in metal-on-metal hips even though they are rare and patient number was small on the reports 
(Weyand et al. 1998, Arora et al. 2003). Numerous studies have demonstrated various 
collagenases and cathepsin K in the synovial membrane-like interface membrane, whereas it is not 
known whether these proproteinases are activated and may overcome their endogenous enzyme 
inhibitors. Low pH and cathepsin K have been shown in aseptic loosening (Konttinen et al. 2001). 
Synovial membrane from patients with hip fracture is not a perfect control for the synovial 
membrane-like interface tissue, however, for ethical reasons it was not possible to take samples 
from implant capsules or synovial membrane-like interface tissue in well fixed implants because 
broken implants are extremely rear although occasionally implant capsule could be obtained for 
example from patients with hip dislocation. Synovial membrane from patients with hip fracture 
was therefore used as control to synovial membrane-like interface. Synovial membrane after hip 
fracture is probably slightly inflammatory, and compared to healthy tissue has probably more pro-
inflammatory cytokines and proteinases (Walakovits et al. 1992). In spite of this, a statistically 
significant and probably biologically relevant difference was noticed between the interface and 
control synovial membranes. 
 
Both MMP-1 (collagenase-1) and MMP-13 (collagenase-3) have been reported to be increased in 
aseptic loosening (Santavirta et al. 1993, Imai et al. 1998, Syggelos et al. 2001). It seems that in 
particular monocyte/macrophages form the primary source of MMPs in prosthetic interface tissue. 
Moreover, cathepsin K has also been described in such tissues in some cells of multinucleated 
giant cells and the monocyte/macrophages (Konttinen et al. 2001, Buhling et al. 2001). In these 
respects the present study confirms these earlier findings by demonstrating that MMP-1, MMP-13 
and cathepsin K tend to increase in aseptic loosening compared to control synovial membrane. As 
this is the first study to measure the amount of degraded collagen in interface membrane we were 
able to perform a correlation analysis between the proteinase positive cells against the proportion 
of collagen degraded. The hypothesis was that if there is a statistically significant correlation, this 
would be compatible with a role of the proteinase in local collagen degradation. If there were no 
correlation at all, this would argue against a significant role of that proteinase in collagen 
degradation. In control synovial membrane these analyses disclosed no statistically significant 
correlations between the three proteinases analyzed and the extent of collagen degradation 
although MMP-1 came close to statistical significance. This might indicate that the fibroblast 
collagenase MMP-1 plays some role in normal extracellular collagen remodeling. The correlation 
between cathepsin K and extracellular collagen degradation was very low and therefore totally 
non-signficant in the control samples. This is compatible with the intracellular, intralysosomal 
nature of the acidic endoproteinase cathepsin K in control samples. If cathepsin K participates in 
collagen matrix remodeling in these control tissues, it occurs probably intracellularly in 
phagolysosomes (Everts et al. 2003). According to similar reasoning in control (patients with hip 
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 fracture) synovial membranes collagen degradation is possibly also mediated by some other 
enzymes, such as neutrophil-derived or mesenchymal cell-derived collagenase 2 (MMP-8) or 
human trypsin 2 (Hanemaaijer et al. 1997, Stenman et al. 2005) or mechanically mediated and 
intracellularly finished. 
 
All proteinases analyzed in the present study were increased in aseptic loosening. Most 
importantly, the extent of extracellular collagen degradation was statistically significantly 
correlated to the number of local cells containing these collagenolytic proteinaseas as 
demonstrated in immunohistochemical staining. In this respect, it is important to note that 
macrophages and fibroblasts do not produce MMPs in response to storaging foreign bodies. In 
contrast, they are soon after synthesis secreted to the extracellular space. Although cathepsin K is 
in part targeted to and activated in lysosomes, also it is in part a proenzyme secreted to the 
extracellular space via a differentially regulated process (Claveau et al. 2001, Hou et al. 2002). 
Therefore, our findings suggest that all these collagenolytic enzymes overcome their endogenous 
inhibitors, are activated to act in concert with each other and participate in pathological peri-
prosthetic tissue destruction. As MMPs can not act in acidic pH and cathepsin K can not act in 
neutral pH, it is possible that some areas of the interface membrane are neutral and some others 
acidic. It is otherwise difficult to explain the highly significant correlation between these enzymes 
in the pathological interface membrane and lack of such correlation in almost healthy, but 
traumatic control synovial membrane. In healthy synovial membrane in particular MMP-1 could 
be responsible for normal collagen tissue remodeling. This is supported by the observation that the 
correlation between MMP-1 and collagen degradation was higher and more significant than that 
between MMP-13 and collagen degradation or cathepsin K and collagen degradation in synovial 
membrane controls. However, the correlation between MMP-1 and collagen degradation was not 
statistically significant (r = 0.86, P = 0.062). This leads to two further conclusions. This 
correlation, although lacking statistical significance, might still be biologically significant. 
Alternatively, maybe this enzyme together with some other enzyme(s) with collagenolytic 
potential is responsible for extracellular collagen degradation in control synovial membranes. 
Present findings also support the hypothesis that cathepsin K, apart from its intracellular 
phagolysosomal function in healthy synovial membrane, has also an extracellular role in 
pathological human tissue collagen degradation in the interface membrane (Kafienah et al. 1998). 
This is compatible with the observations demonstrating that the interface membrane is acidic to 
such an extent that this even leads to demineralization of peri-implant bone (Konttinen et al. 
2001). However, based on our study, it is not possible to impart definite roles for MMPs and 
cathepsin K in this respect. For such an analysis more work e.g. applying antibodies recognizing 
neoepitopes disclosed by MMP-type collagenases and cathepsin K suitable for 
immunohistochemistry will be necessary (Atley et al. 2000, Wu et al. 2002). 
 
 
 
10. CONCLUSIONS 
 
1. This study contributes to the clarification of the reaction of human body and skeleton against 
implant-derived foreign bodies. This is important as implants are used in ever increasing scale for 
treatment of primary hip osteoarthritis, developmental dysplasia of hip joint, hip fractures, post-
traumatic osteoarthritis. More specifically, the study produces new information about mechanisms 
of aseptic loosening of total hip replacement prosthesis and points to some new potencial targets 
for prevention and treatment of loossening. Total hip replacement is the gold standard for 
treatment of advanced hip osteoarthritis refractory to conservative treatment. Foreign body 
inflammation seems to be the force driving local osteoclast formation and peri-implant bone 
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 destruction. Therefore, three members of ADAM family (ADAM8, ADAM9 and ADAM12) have 
all tentatively been identifid as important molecules in foreign body reaction. They were analyzed 
in interface membrane and in in vitro cell stimulation models. We characterized their eventual 
presence and levels in the interface membrane in the patients and their presence and regulation in 
two different in vitro models. ADAMs may mediate fusion of progenitor cells into multinuclear 
foreign body giant cells and osteoclasts. 
 
2. An increased extent of collagen degradation in interface membranes in aseptically loosened hip 
joint implants as compared with synovial membranes from control patients was for the first time 
demonstrated in the present study. Collagen degradation highly significantly correlated with the 
number of local cells containing collagenolytic MMPs and cathepsin K was also demonstrated in 
this study. This may suggest that the foreign body reaction leads to increased production, 
secretion and activation of collagenolytic neutral and acidic proteinses which weaken 
periprosthetic collagenous tissue. This may contribute to loosening of the implants from host 
tissue and extension of the prosthetic joint space so that it to an increasing extent surrounds the 
loosened implant facing the synovial membrane-like lining. 
 
3. In our second in vitro cell stimulation model, the virus-induced target host cell fusion may help 
the virus to safely spread from infected to uninfected cells. It shows that PIV2 is capable to utilize 
host cell fusion molecules ADAMs to spread and form syncytia. The virus-HSY cell system 
provides a novel experimental system to study human cell-to-cell fusion and fusion molecules, 
such as ADAMs. 
 
Fusion molecules, ADAM8, 9 12 
IL-1, IL-6, TNF-α, GM-CSF, 
PGE2, M-CSF, TGF-α etc. 
Wear 
particles 
 
MMPs and cathepsin K 
RANKL, M-CSF, other cytokines and chemokines 
Macrophage activation 
Osteoclast formation 
Implant loosening 
Figure 9. Cascade of wear particle induced marcrophage activation, osteoclast formation and implant 
loosening. 
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 Terminology 
 
Arthrography The radiographic visualization of a joint (as the hip or shoulder) after the injection of a 
radiopaque substance. 22 
 
Arthroplasty Plastic surgery of a joint (as the hip or knee), the operative formation or restoration of a 
joint. 9, 11   
 
Biocompatibility The inherent ability of a material to appropriately interact with the host in a specific 
application. Biocompatibility may be further subdivided into: (1) Hemocompatibility, (2) 
Histocompatibility, and (3) Osteocompatibility. 11
 
Bone marrow stromal cells The bone marrow stroma consists of a heterogeneous population of cells 
that provide the structural and physiological support for giving rise to bone, cartilage, and mesenchymal 
cells. 17 
 
Cysteine A sulfur-containing amino acid C3H7NO2S occurring in many proteins and glutathione and 
readily oxidizable to cystine, abbreviation Cys. 17-19, 40 
 
Cytotrophoblast The inner layer of the trophoblast, interior to the syncytiotrophoblast in an embryo. It 
serves to anchor the embryonic chorion to the maternal endometrium. Cytotrophoblasts are stem cells in 
the chorionic villi. During differentiation, mononuclear cytotrophoblast fuse together into the 
multinucleated syncytiotrophoblasts. 21 
 
Density gradient A column of liquid in which the density varies continually with position, usually as a 
consequence of variation of concentration of a solute. Density gradients are widely used for centrifugal and 
gravity induced separations of cells, organelles and macromolecules. 28 
 
Derivatize Transforms a chemical compound into a product of similar chemical structure, called 
derivative. Generally, a specific functional group of the compound participates in the derivatization 
reaction and transforms the educt to a derivate of deviating reactivity, solubility, boiling point, melting 
point, aggregate state, or chemical composition. Resulting new chemical properties can be used for 
quantification or separation of the educt. 33 
 
Fibrous implant capsule In newly granulation tissue, fibroblasts hypertrophy and actively synthesize 
collagen. With further healing there is an increasing in extracellular material, a decrease in leukocytes, 
macrophages, and blood vessels. The end result is a scar that surrounds the implanted prosthesis composed 
of collagen, fibroblasts, and blood vessels. It is a part of foreign body reaction. 10 
 
Fibrosis A condition marked by increase of interstitial fibrous tissue, fibrous degeneration. 10 
 
Foreign body reaction A benign variation in normal tissue response, caused by the presence of a foreign 
material (e.g., an implantable prosthesis). In soft tissue implantations, a “tissue capsule” composed of de 
novo collagen, multinucleated giant cells, fibroblasts, and blood vessels is normally seen surrounding the 
prosthesis. 8, 10, 13, 39, 44 
 
Fretting To cause corrosion; gnaw into something, acids that fret at the strongest metals. 11
 
Granuloma A nodular inflammatory lesion that contains areas of granulation. 12 
 
Hapten A small separable part of an antigen that reacts specifically with an antibody but is incapable of 
stimulating antibody production except in combination with an associated protein molecule. 39  
 
Hematopoietic Relating to, or involved in the formation of blood cells. 8, 39 
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 Howship’s lacuna A groove or cavity usually containing osteoclasts that occurs in bone which is 
undergoing reabsorption. 22, 23 
 
Isocratic A procedure in which the composition of the mobile phase remains constant during the elution 
process. 33 
 
Niobium A lustrous light gray ductile metallic element that resembles tantalum chemically and is used in 
alloys -- symbol Nb ; called also columbium. 12 
 
PCR An in vitro technique for rapidly synthesizing large quantities of a given DNA segment that involves 
separating the DNA into its two complementary strands, binding a primer to each single strand at the end 
of the given DNA segment where synthesis will start, using DNA polymerase to synthesize two-stranded 
DNA from each single strand, and repeating the process. abbreviation PCR. 31 
 
Podosome The primary sites of integrin stimulated actin polymerization in leukocytes of the monocytic 
lineage. B cells have also been reported to form podosomes.In osteoclasts, podosomes are thought to aid in 
the creation of sealing rings associated with the area of bone resorption. 23 
 
Sense and Anti-sense describe the polarity of nucleic acid molecules. 31, 35 
Sense DNA = a single stranded DNA sequence called coding strand if the sequence is the same as that of a 
messenger RNA except for thymine (T) in place of uracil (U).  
Anti-sense DNA = a template strand DNA, also called the transcribed strand, which is copied to the 
mRNA transcript. 
Anti-sense RNA = a non-coding strand RNA complementary to the coding sequence of RNA transcript or 
mRNA. For example, in in situ hybridization this anti-sense RNA probe is used for detection of the RNA 
transcript.  
Sense RNA = not often used, mostly used in virology; in in situ hybridization the sense RNA probe is used 
for control hybridization. 
 
Shear stress The stress developed parallel to a face of a material when the layers in a cross section are 
gliding along each other. 11 
 
Standard error of the mean The standard deviation of the sample divided by the square root of the 
sample size: . 33 
 
Synovitis Inflammation of a synovial membrane usually with pain and swelling of the joint. 39   
 
Tribology A branch of mechanical engineering that deals with the design, friction, wear, and lubrication of 
interacting surfaces (as bodily joints) in relative motion. 12 
 
Vanadium A grayish malleable ductile polyvalent metallic element found combined in minerals and used 
especially to form alloys (as vanadium steel), symbol V. 12 
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